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Abstract 
 
Introduction: Breast cancer is a major contributor to mortality in women 
worldwide. Although, anthracyclines, such as doxorubicin, are among the most 
valuable treatments for breast cancer, their clinical use is limited due to detrimental 
side-effects such as cardiotoxicity. Additionally, evidence suggests that cancer 
cells are becoming increasingly resistant to chemotherapeutic agents. The 
consequence of poor vascularisation within tumours subsequently leads to a 
nutrient deprived microenvironment which cancer cells are known to adapt to via 
metabolic remodelling and increasing autophagy. Autophagy is an intracellular 
degradation system, which is induced as a survival mechanism in response to 
starvation and other environmental stressors. Recent studies have shown that 
starvation protects non-tumourigenic cells against chemotherapy-induced cell 
death. Furthermore, patients who starved prior to chemotherapy reported reduced 
side-effects. However, these studies investigated the effects of long-term 
starvation, which maybe clinically challenging. Therefore, this concept, under 
shorter and more tolerable periods of starvation still needs to be investigated. We 
hypothesis, that short-term starvation will sensitize breast cancer cells to 
doxorubicin-induced cell death. In order to test this hypothesis this study was 
approached by the following aims: (i) to establish a time point at which MCF12A 
breast epithelial cells are protected against starvation; (ii) to determine the effect of 
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short-term starvation on doxorubicin induced cell death; (iii) to assess autophagy 
and; (iv) to assess these above mentioned aims using an in vivo model. 
 
Methods: MDAMB231 cells and MCF12A cells were starved for 0, 3, 6, 12, 24 and 
48 hours using Hanks Balanced Salt Solution. Cell viability was assessed using the 
trypan blue, MTT and Caspase-Glo assays. MDAMB231 cells and MCF12A cells 
were subjected to the following conditions: (1) control; (2) 5 µM doxorubicin; (3) 
starvation of 3 hours and (4) a combination of starvation and doxorubicin. 
Following treatment an MTT assay to assess cell viability was performed. 
MDAMB231 cells were further examined using Live-Cell Imaging and western blot 
analysis. C57BL6 tumour bearing mice were treated with doxorubicin (5 mg/kg) or 
in combination with starvation of 24 hours. Upon termination of the protocol, 
tumour tissue was assessed using western blot analysis. In both in vitro and in vivo 
analyses cleaved-caspase 3 and cleaved-PARP were used as markers for 
apoptosis, LC3 and p62 as autophagic markers and p-AMPK and p-mTOR as 
markers of oxygen and energy sensing, respectively. 
 
Results and discussion: Three hours of starvation was chosen for in vitro 
experiments since no significant reduction in cell viability or increases in apoptosis 
occurred at this time-point in the normal MCF12A breast epithelial cells. As 
expected, doxorubicin induced a significant decrease in cell viability in the 
cancerous MDAMB231 cells. Short-term starvation in combination with doxorubicin 
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treatment caused a further significant decrease in cell viability in MDAMB231 cells 
compared to the doxorubicin group alone. Interestingly, starved MCF12A cells 
were protected against doxorubicin-induced cytotoxicity as cell viability significantly 
increased. A significant decrease in autophagy was further observed with the 
combined treatment of doxorubicin and starvation which corresponded with a 
significant increase in cell death. In contrast, although the in vivo study also 
demonstrated a significant elevation in cell death and autophagy in response to 
doxorubicin treatment, the combined treatment (starvation and doxorubicin) did not 
have an additive effect when compared to the doxorubicin group alone.  
 
Conclusion: Our in vitro results clearly demonstrate that short-term starvation 
sensitizes breast cancer cells to doxorubicin-induced cell death. Additionally, 
decreased levels of autophagy appear to contribute to this phenomenon of 
sensitization. Although doxorubicin treatment resulted in increased apoptosis in 
vivo, 24 hours starvation in combination with doxorubicin did not sensitize the 
tumours to doxorubicin treatment. Thus, for future in vivo studies more time points 
should be considered in order to translate the beneficial effects of short-term 
starvation observed in our in vitro study to an animal model. 
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Opsomming 
 
Inleiding: Borskanker is ‘n belangrike faktor wat bydrae tot sterftes in vrouens 
wêreldwyd. Alhoewel antrasikliene soos doxorubicin, waardevol is vir die 
behandeling van borskanker, word die kliniese gebruik daarvan beperk deur newe-
effekte soos kardiotoksisiteit. Verder, word daar al hoe meer bewys dat kankerselle 
toenemend weeerstandbiedend word teen chemoterapeutiese middels. Swak 
vaskularisasie van tumore lei tot ‘n mikro-omgewing met beperkte voedingstowwe 
waaby kankerselle kan aanpas deur middel van metaboliese hermodelering en ‘n 
toename in autofagie.  Autofagie is ‘n intrasellulêre degraderingsisteem wat as ‘n 
oorlewingsmeganisme aangewend word tydens verhongering en ander 
omgewingstressors. Onlangse studies het getoon dat verhongering nie-
tumourigeniese (normale) selle teen chemoterapie-geïnduseerde seldood 
beskerm. Verder is daar ook geraporteer dat pasiënte wat gevas het voor 
chemoterapie, verminderde newe-effekte getoon het. Hierdie studies het egter 
gefokus op ‘n relatief lang-termyn vas, wat klinies nogal uitdagend kan wees. 
Daarom moet hierdie konsep nog op korter, meer hanteerbare tye getoets word. 
Ons hipotese is dus dat kort-termyn vas borskankerselle kan sensitiseer tot 
doxorubicin-geïnduseerde seldood. Om hierdie hipotese te toets, is die volgende 
doelwitte gestel: (i) om ‘n tydspunt te bepaal waar MCF12A borsepiteelselle 
Stellenbosch University  http://scholar.sun.ac.za
vii 
 
beskerm is teen verhongering; (ii) om die effek van kort-termyn verhongering op 
doxorubicin-geïnduseerde seldood te toets; (iii) om autofagie te karakteriseer in 
ons model en; (iv) om hierdie doelwitte ook in ‘n in vivo model te toets. 
Metodes: MDAMB231 en MCF12A selle is verhonger vir 0, 3, 6, 12, 24 and 48 ure 
deur van Hanks se gebalanseerde soutoplossing gebruik te maak. 
Sellewensvatbaarheid is bepaal deur middel van trypan blou, MTT en die 
Caspase-Glo tegnieke. MDAMB231 en MCF12A selle is onderwerp aan die 
volgende omstandighede: (1) kontrole; (2) 5 µM doxorubicin; (3) verhongering van 
3 ure en (4) ‘n kombinasie van verhongering en doxorubicin. Na behandeling is die 
sellewensvatbaarheid deur middel van die MTT tegniek bepaal. MDAMB231 selle 
is verder ondersoek deur middel van “Live-Cell Imaging” en die westelike klad 
tegniek. C57BL6 tumor-draende muise is behandel met doxorubicin (5 mg/kg) of 
met ‘n kombinasie van verhongering van 24 ure en doxorubicin. Aan die einde van 
die protokol, is die kankerweefsel geanaliseer deur die westelike klad tegniek. In 
beide in vitro en in vivo analises, is gekliefde- caspase 3 en -PARP as merkers vir 
apoptose, LC3 and p62 as merkers vir autofagie en p-AMPK en p-mTOR as 
suurstof- en energie sensors respektiewelik gemeet. 
 
Resultate en bespreking: Vir die in vitro eksperimente, is ‘n tydspunt van 3 ure 
gekies as gevolg van die feit dat geen afname in sellewensvatbaarheid en ‘n 
toename in apoptose in hierdie tydsgleuf tydens verhongering in die normale 
MCF12A borsepiteelselle plaasgevind het nie. Soos verwag, het doxorubicin 
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behandeling ‘n insiggewende afname in sellewensvatbaarheid in die kankeragtige 
MDAMB231 selle veroorsaak.  Die kombinasie-terapie van verhongering en 
doxorubicin het ‘n verdere verhoging in seldood teweeg gebring in die MDAMB231 
selle, maar het die normale MCF12A borsepiteelselle teen doxorubicin-
geïnduseerde toksisiteit beskerm.  Die kombinasie-behandeling is ook geassosieer 
met ‘n afname in autofagie. Alhoewel, die in vivo studie ook getoon het dat 
doxorubicin alleen insiggewende hoeveelheid seldood teweeggebring het, het die 
kombinasie-behandeling nie die additiewe effek, soos in die in vitro studie, teweeg 
gebring nie.  
 
Gevolgtrekking: Die in vitro resultate het duidelik getoon dat kort-termyn 
verhongering borskankerselle kan sensitiseer vir doxorubicin terapie. Verder het dit 
geblyk dat ‘n afname in autofagie tot die fenomeen van sensitisering bygedrae het. 
Alhoewel doxorubicin behandeling in vivo tot ‘n toename in apoptose in die tumor 
gelei het, het die kombinasie behandeling nie die kankerweefsel ten op sigte van 
doxorubicin gesensitiseer nie. Daar sal dus vir toekomstige in vivo studies meer 
tydsgleuwe van behandeling ondersoek moet word om die optimum 
verhongeringsperiode te vind sodat die in vitro resultate ook in vivo van toepassing 
kan wees. 
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Chapter 1 – Literature Overview 
1.1: The Nature of Cancer 
 
 
The cell: The single most fundamental unit of life. Each of the 100 trillion building 
blocks which constitute the human body, are endowed with an array of organelles 
which display great autonomy, versatility and function collectively to sustain the 
existence of life. Throughout the life span of an organism, cells possess the 
remarkable ability to proliferate, playing a critical role in tissue morphogenesis and 
maintaining the adult tissue by replacing cells that have become damaged or 
suffered attrition after many years of service. This process of cell proliferation is 
subjected to strict homeostatic control; cell death must exactly balance cell 
proliferation in order to maintain a constant number of cells in the human body 
(Evan and Vousden, 2001). A minor disruption in this tightly regulated process can 
trigger the onset of diseases such as cancer which is characterised by continuous 
cell proliferation (Fulda and Debatin, 2006). 
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The multifaceted complexity of this disease challenges a precise definition; 
however there are key characteristics that are inherent to all human cancers. 
These characteristics can be used to describe cancer as an abnormal growth of 
cells caused by multiple changes in gene expression (Evan and Vousden, 2001). 
Such genetic mutations lead to an evolving population of cells that can invade 
tissues and metastasize to distant sites, causing significant morbidity and, if 
untreated, death of the host (Cavallaro and Christofori, 2004). 
 
A recent review by Hanahan and Weinberg (2011) proposed that the hallmarks of 
cancer involve biological capabilities which are enabled by genomic instability and 
tumour promoting inflammation, during the multistep development of human 
tumours. These include: (i) sustaining proliferation signalling - cancer cells 
deregulate growth factor ligands which typically bind to receptor tyrosine kinase 
(RTK) domains. Abnormal RTK activation in human cancers is mediated by four 
principal mechanisms: autocrine activation, chromosomal translocations, RTK 
overexpression, or gain-of-function mutations (Lemmon and Schlessinger, 2010). 
These cells further acquire somatic mutations affecting B-Raf proteins involved in 
the Raf to mitogen activated protein (MAP)-kinase pathway (Bennasroune et al., 
2004; Lemmon and Schlessinger, 2010), subsequently affecting the oncogenic 
phosphatidylinositol 3-kinase pathway (PI3K/Akt) which allows for survivin mRNA 
expression, preventing cell death (Favoni et al., 2000; Zhao et al., 2011). Some 
cancers also acquire a loss of function mutation in the potent tumour suppressor, 
PTEN, which causes a deregulation of the mammalian target of rapamycin (mTOR) 
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which further increases PI3K signalling thus sustaining proliferation (Guertin and 
Sabatini, 2007; Fang et al., 2010; Rodriguez and Huynh-Do, 2012); (ii) evading 
growth suppressors - in contrast to stimulating factors to induce chronic 
proliferation, cancer cells have to further equivocate processes which negatively 
control cell proliferation. The mechanisms by which this can be achieved are 
greatly influenced by the activity of tumour suppressor genes. Mutations in the 
tumour suppressor genes which encode TP53 protein (tumour protein 53) are 
frequent in most human cancers. Such mutations render TP53 protein incapable of 
inducing cell death and inhibiting the progression of cancer cells through the cell 
cycle; (iii) resisting cell death - despite the enormity of DNA damage that may be 
present in cancer cells or which are induced by chemotherapeutic treatments, 
programmed cell death is attenuated via genetic mutation in TP53 (Junttila and 
Evan, 2009); (iv) enabling replicative immortality - as mentioned previously 
progression of normal cells is limited via homeostatic mechanisms, therefore after 
a certain number of divisions, cells enter a state of senescence in which they are 
still viable but no longer proliferate; this leads to eventual death within the 
population. On the contrary, cancer cells are much more resilient and avoid 
senescence and cell death, displaying infinite replicative capacity. Telomeres 
which protect the end of chromosomes have been implicated in playing a key role 
in this immortalisation (Blasco, 2005); (iv) inducing angiogenesis - the tumour 
microenvironment is deprived of nutrients and oxygen, thus in their relentless drive 
to survive, tumour cells develop new blood vessels from existing ones to satisfy the 
nourishment required by these demanding population of cells via activation of 
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vascular endothelial factor (VEGF) (Ferara, 2010; Olive et al., 2009); (vi) invasion 
and metastasis - all cancers are known to invade and destroy adjacent and 
normal tissues. They metastasize via lymphatic channels or blood vessels to other 
regions of the body. As malignant neoplasms progress, the phenotypic 
resemblance once shared with the cells in the tissues they originated from, is lost. 
The loss of E-cadherin, which is a cell adhesion molecule, has been closely 
associated with this characteristic (Cavallaro and Christofori, 2004); (vii) 
reprogramming of energy metabolism - due to their chronic proliferation, cancer 
cells have a high glycolytic rate to meet their metabolic demands. Thus, a 
metabolic switch from mitochondrial oxidative phosphorylation to aerobic glycolysis 
is required to meet this energy demand in hypoxic conditions (Warburg, 1956b); 
(viii) evading immune destruction - cancer cells evade immune surveillance by 
disabling components such as cytotoxic T lymphocytes and secreting TGF- β 
which is an immune-suppressive factor (Yang et al., 2010). The latter two are 
emerging hallmarks (Figure 1.1.1).  
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Figure 1.1.1: The Ten Hallmarks of Cancer and Enabling Characteristics. The hallmarks 
establish an organising principle for elucidating the complexities of neoplastic disease. They include 
sustaining proliferation, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming of energy 
metabolism and evading immune destruction. Underlying these hallmarks are genome instability, 
which generates the genetic diversity and mutability to drive tumour progression, and inflammation, 
which supports multiple hallmark capabilities (Adapted from Hanahan and Weinberg, 2011). 
 
These fundamental hallmarks provide context and perspective, aiding in our 
understanding of all human cancers. Yet, a major question as to precisely how 
cancer cells learn to invade and to undergo the metastases that are responsible for 
90% of cancer mortality, remains unresolved.   
 
According to the Cancer Association of South Africa (CANSA), one in six South 
African men and one in seven South African women will get cancer during their 
lives (Bateman, 2009). In a chapter on lifestyle-induced cancer in South Africa, the 
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authors found that the highest age-standardised cancer death rates are found in 
the coloured population (212.5/100 000), followed by the white (198.9), African 
(126.0) and Asian (121.4) groups. The Western Cape has the highest cancer death 
rates followed by Gauteng (Bateman, 2009).   
1.2: Breast Cancer 
Breast cancer is one of the most prevalent cancers affecting 12.4% of South 
African women. Statistics show a dramatic increase of breast cancer to 15.8% by 
the year 2015. An estimated 8 000 South African women are diagnosed with breast 
cancer every year and about 1 600 (20%) will die (Bateman, 2009) (Figure 1.2.1). 
Figure 1.2.1: Cancer incidence in South Africa (2009). Breast cancer accounts for 12.4%, being 
second most prevalent type of cancer affecting South African women (Adapted from GLOBOCAN, 
2008). 
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Risk factors include high dietary fat intake associated with obesity; duration of 
exposure to female hormones during early menarche and late menopause; alcohol 
consumption; reproductive factors involving nulliparity and late age of first 
pregnancy; chronic use of hormone replacement therapy; exposure to ionising 
radiation during breast development; and genetic inheritance of breast cancer such 
as brca1, brca2 or p53 germline mutations (Richie and Swanson, 2003). 
The human breast is composed of stromal and epithelial elements. The stromal 
elements are comprised of adipose tissue, connective tissue, blood and lymphatic 
vessels, whereas the epithelial elements are composed of numerous branching 
ducts, which connect the lobules leading to the nipple-areolar complex. More than 
95% of breast cancers originate from the epithelial elements and are classified as 
adenocarcinomas (Colditz et al., 2000; Richie and Swanson, 2003). 
It is generally accepted that breast cancer initiates as the premalignant stage of 
atypical ductal hyperplasia (ADH) and further progresses into two major types, in 
situ carcinomas and invasive carcinomas. The in situ carcinomas may arise in 
either ductal or lobular epithelium, remaining there, posing no invasion of the 
underlying basement membrane and infiltration of the surrounding stroma of the 
breast; this constitutes the pre-invasive stage of ductal carcinoma in situ (DCIS).  
In contrast, when the ductal or lobular malignancy extends beyond the basement 
membrane that constitutes the epithelial border and invades the breast stroma, the 
malignancy is considered as an invasive (or infiltrating) ductal or lobular carcinoma 
(IDC) ensuing to a potentially lethal stage. Seventy-five – 80% of invasive cancers 
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are infiltrating ductal carcinomas, while infiltrating lobular carcinomas make up the 
second most common type of invasive cancers (Colditz et al., 2000). 
This linear model of breast cancer progression has been the underlying principle 
for the use of detection methods such as mammography to diagnose and treat 
breast cancer at early clinical stages (Ma et al., 2003). However, one of the most 
challenging aspects faced by clinicians is how to accurately grade these tumours 
as the stages of DCIS and IDC exhibit mitotic activity and cellular differentiation 
both within a tumour and among individual tumours contributing to heterogeneity.  
 
Existing tumour grading systems, subtype the stages of DCIS and IDC into three 
tumour grades. Grade I (well differentiated), Grade II (moderately differentiated) 
and with Grade III (poorly differentiated), being the most malignant resulting in poor 
prognosis (Schnitt, 2001; Ma et al., 2003). 
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Figure 1.2.2: Phenothypical changes in breast malignancies. Phenotypically normal breast 
epithelium (white arrows) and phenotypically abnormal epithelium (black arrows) from ADH, DCIS, 
and IDC from a single breast specimen (case 79) were captured from haematoxylin and eosin 
stained sections (Ma et al., 2003). 
 
As mentioned previously, one of the hallmarks of cancers is resistance to cell 
death. Breast epithelial cell homeostasis requires the balance of cell proliferation 
with a type of cell death called apoptosis (Ma et al., 2003). Apoptosis is defined as 
genetically programmed autonomous cell death, and it occurs in healthy breast 
cells at varying rates during the estrus cycle in response to changes in hormone 
levels (Ma et al., 2003). Apoptosis is also regulated by non-hormonal signals, such 
as heat, radiation, nutrient deprivation, viral infection, hypoxia and increased 
intracellular calcium concentration (Ameisen, 2002).  
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Changes in the genetics of apoptotic regulatory mechanisms may result in an 
increase in cell numbers, as well as the preservation of genetically altered cells, 
which begins the process of tumourigenesis (Junttila and Evan, 2009). 
1.3: Apoptosis 
The term “apoptosis” was first mentioned in an insightful review by Kerr, Wyllie, 
and Currie in 1972 where they described a tightly regulated, energy-dependent and 
morphologically distinct form of cell death. Apoptosis is considered as an integral 
component of significant processes including normal cell turnover, proper 
development and functioning of the immune system, hormone-dependent atrophy, 
embryonic development and chemical-induced cell death. Either too much or too 
little apoptosis has been implicated in many human disorders including 
neurodegenerative diseases, ischemic damage, autoimmune disorders and many 
types of cancer (Elmore, 2007).  
Morphological changes that occur during apoptosis include highly conserved 
chromatin, segregated into distinctly defined bodies within an intact nuclear 
envelope (nuclear pyknosis), cytoplasmic condensation, cells become smaller in 
size, the cytoplasm is dense and the organelles are more tightly packed (cell 
shrinkage), followed by nuclear and cellular fragmentation and rapid phagocytosis 
of apoptotic bodies by adjacent cells (Figure 1.3.1) (Kerr et al., 1994; Ameisen, 
2002).  
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Figure 1.3.1: Schematic view and electron micrographs of morphological changes during 
apoptosis. Electron micrographs depicting: A- condensed chromatin in membrane-enclosed 
nuclear fragments and remnants of the nucleolus, B- nuclear fragmentation, and budding of cell to 
form apoptotic bodies and C- formation of apoptotic bodies (Adapted from Kerr et al., 1994). 
 
Essentially, no inflammatory reaction is associated with the process of apoptosis 
nor with the removal of apoptotic cells, since: (1) apoptotic cells do not release 
their cellular constituents into the surrounding interstitial tissue; (2) they are rapidly 
engulfed and phagocytosed by surrounding cells hence preventing secondary 
necrosis; and, (3) the engulfing cells do not produce anti-inflammatory cytokines 
(Savill and Fadok, 2000; Kurosaka et al., 2003). 
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1.3.1: The Caspases 
The central executioners of apoptosis consist of proteases from the caspase family 
(Kerr et al., 1994; Elmore, 2007; Salvesan and Reidl, 2008). Thus far, 14 
mammalian caspases have been cloned (Budihardjo et al., 1999). Caspases, are a 
subclass of cystein proteases that cleave substrates after aspartic residues 
(Thornberry and Lazebnik, 1998). Similarly, to proteases, caspases are 
synthesized and remain in a latent form (zymogens) until proteolysis and activation 
by other caspases in the cascade occurs.  
 
These pro-enzymes can be classified into 3 classes (Figure 1.3.2). (1) The initiator 
caspases, have long pro-domains of 90 amino acid residues, containing either a 
death effector domain (caspase-8 and caspase-10) or a caspase recruitment 
domain (caspase-2 and caspase-9). Both the death effector domain and the 
recruitment domain interact with complementary domains on adaptor proteins 
which aid in auto proteolysis. (2) The executioner or effector caspases contain 
short pro-domains (caspases 3, 6 and 7). (3) Inflammation caspases are mainly 
involved in cytokine maturation (caspases 1, 4, 5, 12, and 14) (Grütter, 2000). 
 
Collectively, in a classically formed cascade, initiator caspases (upstream in the 
cascade) cleave and activate effector caspases (downstream in the cascade) 
resulting in rapid caspase mobilization and cascade amplification, ultimately 
culminating in apoptotic cell death by two central pathways: the extrinsic or death 
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receptor pathway and the intrinsic or mitochondrial pathway (Thornberry and 
Lazebnik, 1998; Elmore, 2007; Salvesan and Reidl, 2008).  
 
 
 
Figure 1.3.2: Schematic representation of effector and initiator caspases and their domains 
(Petronelli et al., 2005). 
 
1.3.2: The Extrinsic Pathway 
The extrinsic or death receptor-mediated pathway is initiated by the binding of 
ligands of the death receptor super-family [Fas ligand (CD95), tumour necrosis 
factor-α (TNF-α), TRIAL and Apo-3L] to their associated cell surface receptors. 
Each of these death receptors contains a cytosolic domain or death domain. Once 
bound to their respective ligands and with the aid of death domain-mediated 
protein-protein interactions, intracellular adapter proteins are recruited to the cell 
membrane, creating a multi-protein complex commonly known as the death-
inducing signaling complex (DISC). DISC in turn, activates caspase-8/10 which 
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activates caspase-3, thereby inducing apoptosis. In Fas signaling, the binding of 
Fas ligand to the Fas death receptor leads to its association with an adaptor 
protein known as Fas-associated-death-domain (FADD). FADD contains a death 
effector domain (DED) which in turn binds to the DED of procaspase-8 forming 
DISC. DISC subsequently activates caspase-8, resulting in the cleavage and 
activation of caspase-3 and Bid (BH3 interacting domain death agonist). 
Importantly, the activation of procaspase-8 can be inhibited by recruitment of c-
FLIP, a protease-deficient caspase homolog widely regarded as an apoptosis 
inhibitor. In many cell types, activation of the extrinsic pathway also requires the 
activation of the intrinsic pathway to achieve complete execution of cell death 
(Kroemer, 2003; Thorburn, 2004). 
1.3.3: The Intrinsic / Mitochondrial Pathway 
Mitochondria are thought to be the “gatekeepers” of apoptotic machinery as they 
are the principal organelles involved in mediating most apoptotic pathways in 
mammalian cells (Kroemer, 2003; Thorburn, 2004). The intrinsic pathway is 
activated in response to various stress stimuli, including DNA damage, heat, 
gamma and ultraviolet radiation, actions of onco-proteins and tumour suppressor 
genes (p53), viruses as well as chemotherapeutic agents (Kroemer, 2003). 
The intrinsic pathway involves the bcl-2 family of pro-apoptotic (Bax, Bid, Bak) or 
anti-apoptotic (Bcl-2, Bcl- XL) proteins (Figure 1.3.3). Activation of pro-apoptotic 
factors results in their translocation to the mitochondrial membrane, subsequently 
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depolarizing voltage-dependent mitochondrial channels, releasing cytochrome c 
(Cyt c) and smac/DIABLO which are mediators of apoptosis. There are both 
positive and negative regulators that interact in this pathway as smac/DIABLO 
protein prevents the activation of inhibitor of apoptosis (IAP) proteins, subsequently 
inhibiting caspase-3. The crosstalk between the extrinsic and intrinsic pathways is 
mediated by Bid. When cleaved and activated by caspase-8, Bid triggers Cyt c 
release from the mitochondria. It is crucial for this process to be tightly regulated, 
as it decides the fate of every cell in the human body thus, ensuring the existence 
of mankind. It is well established that apoptosis contributes to cell death in tumours 
treated with various anticancer agents (Kerr et al., 1994; Ameisen, 2002; Simstein 
et al., 2003). 
 
Figure 1.3.3: Schematic representation of the intrinsic and extrinsic pathways of apoptosis 
(Lamkanfi and Dixit, 2010). 
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Standard treatment, which includes maximal surgical removal of the tumours and 
post-operative radiation therapy combined with doxorubicin (DXR) chemotherapy, 
still yields unsatisfactory results. This is mainly due to the high resistance of 
infiltrative tumour cells to programmed cell death (Verheij, 2000). 
1.4: Doxorubicin 
First developed in the 1970’s, derived from a metabolite of Streptomyces peucetius 
var. Caesius, the anthracycline, doxorubicin (DXR) has become a highly effective 
anti-neoplastic agent used in the treatment of breast cancer and various other 
cancers (Octavia et al., 2012). Several mechanisms have been postulated to 
describe the apoptotic effects of anthracyclins which mainly involve: free radical 
. 
 
Figure 1.4.1: Doxorubicin intercalates into DNA and stabilises the cleavable complex 
(Frederick et al., 1990). 
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formation subsequently leading to DNA and cell membrane damage, disruption of 
DNA topoisomerase II  (TOP2A) and also DNA intercalation, resulting in inhibition  
of DNA replication, synthesis and strand break related DNA damage (Figure 1.4.1) 
(Gewirtz, 1999). Chemotherapy using DNA intercalators have proven to be one of 
the most successful approaches to cancer treatment. Although DNA intercalators 
are believed to inhibit DNA polymerases and topoisomerases, resulting in the 
induction of apoptosis in tumour cells, other factors potentially inhibited by the 
anthracycline antibiotic have been successfully elucidated. One of the major 
targets of doxorubicin (DXR) was shown to be DNA methyltransferase 1 (DNMT1) 
which is a primary enzyme responsible for the maintenance of DNA methylation on 
genomic DNA. Doxorubicin-induced inhibition of DNMT1 resulted in drug-induced 
apoptosis in human cancer cells indicating that the levels of DNMT1 in tumour cells 
may affect the effectiveness of doxorubicin in chemotherapy (Yokochi and 
Robertson, 2004).  
 
Recently, a study conducted by Lee and colleagues (2010) using cDNA microarray 
analysis, identified 18 genes which mediated DXR- induced cell death; mainly via 
poly (ADP-ribose) polymerase cleavage (PARP), and activation of caspase-3. Poly 
(ADP-ribose) polymerase (PARP) is a nuclear enzyme, present abundantly in 
eukaryotic cells. It is activated in response to DNA strand breakage which is 
induced by chemotherapeutic agents and various other environmental stresses. 
When activated, the enzyme increases its catalytic capacity and rapidly binds to 
damaged DNA; this in turn initiates an energy-consuming cycle by transferring 
ADP ribose units from NAD to nuclear proteins to induce DNA repair (Munoz-
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Gamez et al., 2005; Lee et al., 2002). Since, this process is ATP-dependent, 
extensive DNA damage subsequently cleaves PARP resulting in the rapid 
depletion of the intracellular NAD and ATP pools, slowing the rate of glycolysis and 
mitochondrial respiration and eventually leading to the proteolytic cleavage of 
PARP by caspase-3 ultimately resulting in apoptotic cell death (Pacher et al., 
2002).  
 
In contrast, other genes such as TP53 and CD95 have also been implicated in 
inducing p53- mediated apoptosis (Lorenzo et al., 2002). Furthermore, it was also 
demonstrated that treatment of the cells with DXR resulted in reactive oxygen 
species (ROS) generation and a concomitant increase in apoptotic cell death 
through the mitochondrial death pathway independent of p53 (Luanpitpong et al., 
2012). Additionally, different doses of doxorubicin activate different regulatory 
mechanisms to induce either apoptosis or cell death through mitotic catastrophe. 
Specifically, high dose DXR induced apoptosis through activation of NF-kB, p38, c-
Jun N-terminal kinase, and caspases; where low doses of DXR resulted in loss of 
cell membrane integrity and cell death through mitotic catastrophe (Eom et al., 
2005). 
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1.4.1: Side-effects of Doxorubicin Therapy 
 
Chemotherapy using DNA intercalators such as DXR to induce its cancer 
eradicating properties has proven to be one of the most successful approaches to 
cancer treatment; however it induces various side- effects such as hematopoietic 
suppression, nausea, vomiting, extravasation and alopecia (Octavia et al., 2012). 
Yet, the most detrimental side-effect induced by anthracyclines is its cumulative 
and dose-dependent cardiac toxicity which has been a major concern of 
oncologists in cancer therapeutic practice for decades (Singal and Iliskovic 1998; 
Zhang et al., 2009). DXR-induced cardiotoxicity may be recognized by symptoms 
such as asymptomatic electrocardiography (ECG)-changes, pericarditis and either 
acute or chronic cardiomyopathy. 
 
Occurring during or immediately after a high dose of chemotherapy, acute 
cardiomyopathy develops into acute tachyarrhythmia and acute heart failure; these 
effects are however, thought to be reversible and can be clinically controlled 
(Schimmel et al., 2004). Techniques employed by clinicians to detect acute 
myocardial related injuries directly after a high dose of DXR involves the detection 
of decreases in ejection fractions as well as elevated plasma concentrations of 
cardiac troponin I (Tn I). This biomarker is a highly specific indicator of poor cardiac 
output as well as left ventricular injury (Schimmel et al., 2004). In contrast, chronic 
DXR-induced cardiac toxicity is dependent on the dose of chemotherapy 
administered to a patient (Arola et al., 2000; Zhang et al., 2009). Under these 
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circumstances, patients become predisposed to developing an irreversible form of 
dilated cardiomyopathy, which may occur years later after receiving the last DXR 
treatment, manifesting into a poor prognosis. Acute and chronic DXR-induced 
cardiac toxicity, equally contribute to cardiac dysfunction, cardiomyopathy, 
ultimately terminating in severe heart failure and death (Wallace, 2003; Zhang et 
al., 2009). 
 
Evidently, cardiotoxicity also occurs at low dose administration as a result of 
varying susceptibility among patients (Jain, 2000). A study conducted by Lipshultz 
et al. (1995) revealed that gender difference is a key risk factor, as females 
suffered more severe cardiotoxicity with more depressed contractility thus, 
indicating a greater susceptibility to the toxic effects of doxorubicin. Age is an 
additional risk factor as children younger than 4 and elders older than 65 showed 
greater risk of developing doxorubicin-induced cardiotoxicity. Frequently, patients 
who are administered a combination of chemotherapeutic drugs, mediastinal 
radiotherapy and others who have hypertension, diabetes mellitus, liver disease, 
and a history of previous cardiac disease further correlates with an increased risk 
of cardiotoxicity (Jain, 2000; Hershman et al., 2008). Although, investigations on 
DXR-induced cardiotoxicity have persisted for decades, a patient’s onset of 
developing symptomatic cardiomyopathy (within or up to 15 years later post 
chemotherapy) is unpredictable. This strongly indicates that different mechanisms 
may be involved in doxorubicin-induced cardiomyopathy. 
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Most studies have implicated free radical-induced oxidative stress (ROS) as a 
pivotal role player in the induction of cardiomyocyte death in DXR-induced 
cardiotoxicity (Figure 1.4.2). Due to the fact that DXR is cationic in nature, it 
remains in the inner mitochondrial membrane space disrupting the electron-
transport chain and causing mitochondrial DNA lesions which subsequently 
generates vast amounts of ROS (Jehle et al., 2001). These DNA lesions may also 
be caused directly by DXR leading to activation of extracellular-regulated kinase 
(ERK1/2), followed by increased phosphorylation of p53, the latter further up-
regulating p53-downstream genes such as Bax. This eventually leads to intrinsic 
apoptotic cell death (Figure 1.4.2) (Liu et al., 2006). In the 1980’s, DXR has shown 
to have a high affinity for iron, forming complexes which lead to lipid peroxidation, 
reduced levels of antioxidants, sulfhydryl groups and further induction of ROS 
resulting in cell damage (Doroshow et al., 1980; Wallace, 2003; Xu et al., 2005; 
Neilan et al. 2007).  
 
Another study reported that the conversion of DXR to an unstable semiquinone 
intermediate by an endothelial nitric oxide synthase reductase domain, further 
increases ROS production (Neilan et al. 2007). This generation of ROS, increases 
intracellular calcium levels which, in turn, further increase ROS production. The 
calcium and ROS overload triggers mitochondrial permeability transition (MPT), 
resulting in mitochondrial swelling, loss of membrane potential and outer 
membrane rupture, ultimately causing  apoptosis of cardiomyocytes via  activation 
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of the intrinsic apoptotic pathway, mediated by the release of cytochrome c  and 
apoptosis inducing factor (Figure 1.4.2) (Camello-Almaraz et al., 2005).  
 
The extrinsic pathway of apoptotic death is also involved in DXR-induced 
cardiomyocyte apoptosis. Deregulation of transcription factors leads to FAS and 
subsequent caspase-8 activation, terminating in apoptotic cell death (Figure 1.4.2) 
(Nakamura et al, 2000). Interestingly, the heat-shock family of proteins plays a 
distinct role in these processes. Heat shock proteins are well recognized for their 
involvement in inducing anti-apoptotic proteins. However, it has become apparent 
that ROS activates HSF-1, which produces more Hsp25, which stabilizes p53 and 
increases the production of pro-apoptotic proteins (Figure 1.4.2) (Vedam et al., 
2010). 
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Figure 1.4.2: Interaction between doxorubicin with the various apoptotic pathways in the 
cardiomyocyte. The left side of the figure shows how doxorubicin begins to generate ROS and the 
dissociation of the eNOS into monomers. Doxorubicin also enters the mitochondria, causing the 
release of cytochrome C oxidase, and also prolongs the opening time of calcium channels in the 
sarcoplasmic reticulum, which activates calcineurin. Akt phosphorylation inhibits Bad activation and 
is one of the main anti-apoptotic pathways. Oxidative stress activates HSF-1 and produces more 
Hsp25, which increases the pro-apoptotic proteins. Abbreviations: Dox: doxorubicin, Doxol: 
doxorubicinol, Doxq: doxorubicin semiquinone, ROS: reactive oxygen species, SE: sarcoplasmic 
reticulum, HSF: heat-shock factor, Hsp: heat-shock protein, CytC: cytochrome C, and Casp3: 
caspase 3 (Adapted from Octavia et al., 2012). 
 
 
Evidently, researchers have established various mechanisms involved in DXR-
induced cardiotoxicity. Unfortunately, much remains to be elucidated in order to 
effectively implement pharmacological interventions and treatment options 
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improving prognosis of patients. However, this is not the only challenge that 
researchers and clinicians are faced with. In addition to the fact that DXR induces 
damaging effects on the heart, cancer cells are becoming inherently resistant to 
DXR-induced cell death. 
 
1.5 Chemo-resistance 
 
The resistance of cancer cells to chemotherapy (chemo-resistance) is a 
multifaceted challenge faced by oncologists and their cancer victims. Initially, 
patients are susceptible to chemotherapy (chemo-sensitive) and cancer free 
directly after their course of treatment. However, 50% to 70% of patients relapse 
within one year as a result of poor surgical outcomes in which whole tumours are 
not completely resected subsequently leading to the formation of another tumour. 
In most cases of relapse, the adenocarcinoma cells acquire a chemo-resistant 
phenotype (Chang, 2011; Castells et al., 2012). In breast cancer specifically, 
chemo-resistance is often associated with the progression of the malignancy from 
a hormone-dependent, non-metastatic, anti-estrogen-sensitive phenotype to a 
hormone independent, invasive, metastatic, anti-estrogen-resistant phenotype 
(Simstein et al., 2003). 
 
Literature has shown that the topoisomerase II enzyme, which is mainly targeted 
by DXR to induce its cancer eradicating properties, is associated with drug 
resistance via two major routes. Firstly, many cancer cell lines display reduced 
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expression of the enzyme, and secondly, there are a number of mutations to 
topoisomerase I/II that prevent or reduce the affinity of drug binding (Mellor and 
Callaghan, 2008). This type of chemo-resistance highly correlates with genetic 
alterations within the cancer cells. For example, loss of p53 function as a result of 
genetic mutations prevents the initiation of apoptosis following chemotherapeutic 
treatment, thus conferring resistance (Yang et al., 2003). Cancer cells are capable 
of recruiting various DNA repair pathways such as base excision, nucleotide 
excision, mismatch or direct repair of damage introduced by chemotherapy 
(Madhusudan and Middleton, 2005).  
 
Furthermore, increased mRNA levels of ERCC1 (excision repair cross-
complementing) protein, which plays a significant role in determining success or 
failure of chemotherapy, were observed in drug-resistant cell lines (Lord et al., 
2002; Rosell et al., 2002). Apart from these genetic mutations, it has become well 
established that cancer cells also express reduced sensitivity to apoptosis. Clinical 
data in advanced breast cancer patients revealed that overexpression of the anti-
apoptotic Bcl-2/Bcl-x L proteins correlated with chemotherapy resistance (Sjostrom 
et al., 2002). In breast cancer, deregulation of the Akt signaling pathway and 
amplification of the Akt gene were implicated in promoting cell proliferation and 
survival and thus chemo-resistance (Nicholson and Anderson, 2002). Other 
mechanisms involved include, active efflux of the chemotherapeutic agent from the 
tumour cell; modification of drug targets; changes or mutation in mitotic checkpoint 
signals; drug sequestration and detoxification of cytotoxic agents (Chang, 2011). A 
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more recent and evolving concept strongly associates chemo-resistance with the 
tumour microenvironment as it evidently influences the growth of cancer which 
have an impact on the outcome of therapy (Meads et al., 2009). Interestingly, non-
malignant cells in this niche play a supportive role in cancer growth as well (Basak 
et al., 2009). In support of this notion, Meads et al. (2009) reported that the tumour 
microenvironment induces rapid signaling which mediates cancer cell survival and 
removal of this microenvironment will ameliorate chemo-resistance. 
 
The microenvironment (stroma) consists of endothelial cells, carcinoma-associated 
fibroblasts, adipocytes, mesenchymal cells, mesenchymal stem cells and cells 
from the immune and inflammatory systems. These stromal cells communicate 
with each other, also known as oncologic trogocytosis (Raffi et al., 2012).  
Accumulating evidence shows that the cells residing in this niche could potentially 
induce chemo-resistance in tumour cells by: (i) cell to cell and cell to matrix 
interactions which influences cancer cell sensitivity to apoptosis; (ii) local release of 
soluble factors such as interleukin-6 (IL-6) that promote survival and tumour growth 
as there is communication via paracrine factors between stromal and tumour cells 
(Castells et al., 2012); (iii) direct cell-cell interactions with tumour cells (Raffi et al., 
2012; Lis et al., 2011; Scherzed et al., 2011); iv) the generation of specific niches 
within the tumour microenvironment which consist of subpopulations of tumour 
cells that may gain a survival advantage following initial drug exposure, and (v) the 
conversion of the cancer cells into cancer-initiating cells or cancer stem cells  
(Teng et al., 2011). Additionally, in 1979, Sutherland et al. reported a higher 
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resistance against DXR-induced cell death when cells were organized spherically 
in culture in comparison to a monolayer.  
 
Although the cross talk between the stromal cells and tumour cells are crucial in 
developing tumours, cells located in the intra-tumour, avascular regions face other 
challenges posed by this niche. This specific region is characterized by low 
nutrients and oxygen (hypoxia), acidic extracellular pH and populations of 
quiescent cells which subsequently impact on the success of chemotherapy in 
solid tumours (Izuishi et al., 2000). The rapid rate of tumour growth requires 
increased levels of energy production through cellular metabolism. However, 
inadequate vascularisation progressively leads to a tumour hypoxic environment. 
The hypoxic environment requires that energy demands are satisfied through 
glycolytic pathways rather than the more efficient oxidative phosphorylation route 
known as the “Warburg Effect” (Sutherland et al., 1998; Dang and Semenza, 
1999). 
 
Additionally, the high interstitial pressure prevents clearance of metabolic end-
products such as lactic acid (Dang and Semenza, 1999). Enhanced hypoxia further 
leads to the up-regulation of growth factors such as platelet-derived growth factor B 
(PDGF-B), transforming growth factor β (TGF-β), insulin-like growth factor 2 (IGF-
2), and epidermal growth factor (EGF) (Tredan et al., 2007). Angiogenesis is 
regarded as the key contributor of metabolites and oxygen found in large tumours 
thus, allowing for tumour progression (Izuishi et al., 2000). An additional prevailing 
Stellenbosch University  http://scholar.sun.ac.za
28 
 
mechanism thought to be involved in chemo-resistance is autophagy. A study 
conducted by Yoon et al., (2012) concluded that the induction of autophagy by 
genotoxic stress is likely to contribute to the sustained survival of breast cancer 
cells through DNA repair regulated by ataxia telangiectasia mutated (ATM)-
mediated activation of DNA-dependent protein kinase catalytic subunit (DNA–
PKcs), and PARP. Another study has also implicated autophagy in either 
sensitising cancer cells to chemotherapeutic agents through ‘recycling’ damaged 
cellular contents or intensifying chemotherapy-induced apoptosis (Zhuang et al., 
2009). 
 
1.6 Autophagy 
 
First described in the 1960’s, autophagy is characterised by the development of 
autophagosomes that engulf bulk cytoplasm, organelles and other cellular 
components such as proteins before fusing with the lysosome, which results in 
mass proteolysis (Figure 1.6.1). This has been shown to occur mainly in response 
to nutrient starvation, hypoxia, ATP depletion or signals prompting cellular 
remodelling and is mainly controlled via the mTOR signalling cascade. Although it 
has become widely accepted as a mode of programmed cell death, autophagy 
(type II cell death) is yet to be definitively defined as such (Amaravadi et al., 
2011).The current hypotheses in the literature reveals, that autophagy might more 
accurately be described as a cell survival mechanism that acts alongside cell death 
but does not necessarily lead to it. 
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Figure 1.6.1: Schematic diagram of the steps involved in the process of autophagy. 
Autophagy begins with the formation of the phagophore or isolation membrane (vesicle nucleation 
step).The expansion of the phagophore into an autophagosome (vesicle elongation). The 
autophagosome can engulf bulk cytoplasm non-specifically, including entire organelles or targeted 
cellular constituents specifically. When the outer membrane of the autophagosome fuses with an 
endosome (forming an amphisome before fusing with the lysosome) or directly with a lysosome 
(docking and fusion steps), it forms an autophagolysosome. Finally, the sequestered material is 
degraded inside the autophagolysosome (vesicle breakdown and degradation) and recycled 
(adapted from Meléndez and Levine, 2009). 
Although cell death through autophagy has been suggested as a mechanism of 
tumour suppression (Sun et al., 2009; Liang et al., 1999), it still remains a 
controversial matter whether autophagy leads to tumour formation or suppression. 
In addition, a recent study by Zhang et al., (2009), revealed that hypoxia induces 
mitochondrial autophagy to prevent an increase in the level of reactive oxygen 
species and subsequent cell death. Thus, when viewed dynamically, it is becoming 
apparent that autophagy acts to delay cell death and may only manifest as such 
due to a failed attempt to keep cells alive. However, this can only occur once 
autophagy has progressed and persisted beyond the so-called ‘point of no return’ 
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(PONR), resulting in apoptosis or possibly even necrosis (Loos and Engelbrecht, 
2009; Sun et al., 2009).  
There is however, a great lack of knowledge, regarding the progression of 
autophagy with time in oxygen and nutrient deficient tumour micro-environments. 
This could be due to autophagy being recognized predominantly as a death 
mechanism in the cancer environment as well as due to the lack of investigation on 
autophagy in the different tumour microenvironments.  
1.6.1 The role of autophagy in nutrient deprivation 
Functional autophagy requires the recruitment of multiple autophagy-related (Atg) 
gene products. These genes are responsible for regulating the well-orchestrated 
processes of nucleation, elongation and maturation of the phagophore membranes 
around the targeted cargo for degradation (autophagosomes), and their 
subsequent fusion with lysosomes forming autophagolysosomes (Figure 1.6.2) 
(Yang and Klionsky, 2010). A commonly-associated mechanism by which 
autophagy is activated in response to nutrient and growth factor deprivation 
involves the activation of AMP-activated protein kinase (AMPK) and subsequent 
inhibition of the mammalian target of rapamycin (mTOR). These proteins tightly 
maintain and regulate the energy status of the cell and have been implicated in 
playing a role in autophagy in many human cancers (DiPaola et al., 2008). AMPK 
plays a key role in the regulation of energy homeostasis. This kinase is 
phosphorylated at the Thr172 residue leading to its activation in response to a low 
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AMP/ATP ratio due to cellular stresses such as starvation. mTOR acts as a sensor 
for energy and amino acids, balancing the availability of nutrients and cell growth. 
 
Figure 1.6.2: Regulation of autophagy under nutrient deprivation and its interaction with 
central carbon metabolism. The major extra-cellular nutrient sensing pathways, controlled by 
PI3K-I and adenosine monophosphate activated kinase (AMPK) tightly regulate autophagy through 
mTOR signaling, although other mTOR independent mechanisms exist. Under nutrient-replete 
conditions autophagy is inhibited by mTOR and inactivation of the ULK1 complex. Metabolic stress 
relieves this inhibition to activate autophagy, and AMPK is activated. AMPK inhibits mTOR by 
activating its negative regulator, the tuberous sclerosis protein 2 (TSC2) and inhibiting its positive-
regulatory subunit, Raptor. The ULK1 complex activates the vacuolar sorting protein34 (hVPS34)- 
and Beclin1-containing complexes (complex I and complex II), to initiate phagophore formation. 
Phagophores nucleate and expand around the cargo encapsulating it and targeting it to lysosomes 
for degradation. Degradation products of autophagy substrates may re-enter glycolysis and the 
TCA cycle for anabolic as well as catabolic processes leading to generation of energy and biomass 
production (Mathew and White, 2011). 
 
 
When nutrients are available, AMPK is inactive allowing for mTOR activation via 
phosphorylation at the Ser 2448 position. Activated mTOR binds and inactivates 
two components of the Unc-51-like kinase (ULK1) complex, ULK1 and Atg13, 
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which are essential positive regulators of autophagosome formation (Kim et al., 
2011) (Figure 1.6.2). This leads to the subsequent inhibition of phagophores 
becoming nucleated, thus inhibiting autophagy (Hasokawa et al., 2009; Kim et al., 
2011). In contrast, when nutrients are limited, AMPK is activated, subsequently 
inhibiting or reducing mTOR activity and inducing autophagy. This provides a 
controlled homeostatic system that ensures the necessary integration of growth 
control signals with nutrient availability and catabolism. 
 
When mTOR activity is inhibited in this scenario, it induces autophagy by 
dissociating from the ULK1 complex, freeing it to trigger autophagosome 
nucleation and elongation (Hasokawa et al., 2009; Kim et al., 2011). The 
elongation of autophagosome membranes involves microtubule-associated protein 
1A/1B-light chain 3 (LC3). LC3 is a soluble protein with a molecular mass of 
∼17 kDa that is distributed ubiquitously in mammalian tissues and cultured cells.  
The cytosolic form of LC3 (LC3-I) is conjugated to phosphatidylethanolamine to 
form LC3-phosphatidylethanolamine conjugate (LC3-II), which is recruited to 
autophagosomal membranes (Tanida et al., 2004). Autophagosomes then fuse 
with lysosomes to form autolysosomes which are degraded by lysosomal enzymes. 
Simultaneoulsy, LC3-II in the autolysosomal lumen is degraded (Tanida et al., 
2004). Thus, lysosomal turnover of the autophagosomal marker LC3-II reflects 
starvation-induced autophagic activity, and detecting LC3 by western blotting has 
become a reliable method for monitoring autophagic activity (Mizushima and 
Yoshimori, 2007). Importantly, although mTOR signaling tightly regulates 
Stellenbosch University  http://scholar.sun.ac.za
33 
 
autophagy in response to starvation, there are various other mechanisms 
independent of mTOR, through which autophagy can be regulated (Meijer and 
Codongo, 2004; Jung et al., 2010). 
 
The process of selecting cargo for autophagic degradation involves ubiquitin 
modifications of targeted proteins and cellular constituents. LC3-II binds 
p62/SQSTM1, an adapter protein that targets these ubiquitinated protein 
aggregates which are selected for degradation via autophagy (Pankiv et al., 2007).  
Specifically, p62 contains an ubiquitin-binding domain (UBA domain), a LC3- 
interacting region (LIR domain). The UBA domain is required for the appropriate 
localization of p62 within cytoplasmic aggregates such as misfolded and 
ubiquitinated proteins, referred to as p62 bodies. These p62 bodies then bind to 
LC3 II on the autophagosomal membranes via the LIR domain and are degraded 
when autophagosomes fuse with lysomes (Pankiv et al., 2007). Thus, p62 plays a 
key role as an adaptor between the autophagic machinery and the ubiquitinated 
substrates, regulating cell survival, as the disposal of toxic aggregates is essential 
for the prevention of cell death in several pathological situations in which p62 is a 
component of these aggregates (Vadlamudi and Shin, 1998; Pankiv et al., 2007). 
Since, LC3-II (present on the inner and outer membrane of the autophagosome) 
and p62 are both degraded in the autolysosome during autophagy; the lysosomal-
dependent turnover of these proteins, especially p62, has emerged as a valid 
measure of autophagic flux (Bjorkoy et al, 2005). Additionally, the intracellular 
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accumulation of p62 and an increase in p62 bodies may indicate a defect in 
autophagic degradation (Komatsu et al., 2007; Mathew et al., 2009). 
 
In mammals, all cells have internal nutrient stores such as glycogen and lipid 
droplets for use during starvation. When required, these stores are broken down 
enzymatically (glycogen phosphorylase and hormone-sensitive lipase). Autophagy 
plays a pivotal role in providing access to such undedicated nutrient stores, thereby 
supporting mammalian cells during nutrient deprivation. Evidence of this has been 
shown with lymphocytes which possess the ability to consume environmental 
nutrients, depending on growth factor availability. In the absence of such growth 
factors, energy is maintained through induction of autophagy, with lymphocyte cells 
shrinking ~50% in size during 3 months as result of self-cannibalizing (Lum et al., 
2005). An animal study observed that starved pups with defective autophagy died 
within 24 hours of starvation since both circulating and tissue amino acid levels are 
reduced, and AMPK is activated in the heart, which showed electrocardiographic 
changes similar to those observed with severe myocardial infarction (Kuma et al., 
2004).  
 
In human adult starvation, autophagy also has a central role, increasing within 24 
hours in liver, pancreas, kidney, skeletal muscle, and heart; the brain is spared 
(Mizushima et al., 2004). Pharmacological inhibition of autophagy, early in 
starvation culminates in cardiac dysfunction (Kanamori et al., 2009). After 2 days 
(48 hours) of starvation, levels of autophagy remain elevated in the both cardiac 
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and skeletal muscle and return to basal levels in the liver. However, liver mass 
decreases rapidly indicating a correlation between the failure of biosynthesis to 
balance basal consumption of autophagy by the liver (Komatsu et al., 2005). With 
the simultaneous decrease in liver mass, breakdown of muscle and adipose tissue 
feeds the liver, which exports glucose and ketone bodies required by the brain. 
 
In the context of human cancers, it is known that cancer cells alter metabolism to 
suit their specific growth requirements and express chronic proliferation and thus 
requiring an increased need for energy and a carbon/nitrogen sources for biomass 
production. As a major contributor to energy substrates during stressful conditions, 
autophagy supports cancer cells to meet their enhanced metabolic demands. This 
may be achieved in the form of lipophagy, in which autophagy provides fatty acids 
for β-oxidation that generates acetyl-CoA in mitochondria to support the TCA cycle. 
Additionally, autophagic degradation of pre-existing intracellular proteins forms an 
abundance of amino acids in cancer cells (Yuneva et al., 2007; Rabinowitz and 
White, 2010). These free amino acids subsequently enter into central carbon 
metabolism at multiple points that include pyruvate, acetyl-CoA and TCA 
intermediates such as α-ketoglutarate (α-KG) (from glutamine) and oxaloacetate 
(from aspartate) (Rabinowitz and White, 2010). Evidently, Guo et al. (2011) 
showed that cancers with Ras mutations and malfunctioning autophagic machinery 
resulted in impaired cell growth, suggesting that targeting autophagy and 
mitochondrial metabolism are valuable new approaches to treat these aggressive 
cancers. 
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The role that autophagy plays in cancer metabolism remains to be entirely 
elucidated. Not much is known about how autophagy selectively accesses major 
energy sources such as lipids and carbohydrates, and to what extent do these 
sources contribute to stress survival. Another interesting and yet unanswered 
question is how tumours with autophagy defects, and mitochondrial and TCA cycle 
impairments, sustain tumour growth. Ultimately, how can scientists manipulate the 
metabolic role of autophagy in tumour progression clinically to ameliorate chemo-
resistance? Answers to these imperative questions may translate into beneficial 
treatment regimens for cancer sufferers. 
 
This lack of knowledge raises areas of concern and questions which require clear 
answers: What is the specific role of autophagy in tumours and what is the 
contribution of autophagy to cellular survival during therapy resistance? Whether 
cell death by autophagy or autophagy itself actually occurs in breast cancer is still 
largely undetermined, therefore further investigation in this field is required. 
Another concept that still remains to be explored is the possibility that malignant 
cells in the advanced stages of the carcinogenesis undergo autophagy as a pro-
survival mechanism. 
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1.7 Starvation 
 
During ancient times, as far as the beliefs of Egyptians, legendary philosophers 
and doctors of western medicine like Hippocrates and Paracelus believed that 
therapeutic fasting should be practiced as a method of healing various health 
conditions. From an infant’s refusal to eat due to a common cold to a cancer 
patients loss of appetite during chemotherapy, it appears that the body’s innate 
response to, or perhaps therapy for combating against disease and infection, is to 
limit one’s nutritional intake. Since, such a phenomenon persists in nature, the 
concept of controlled nutrient starvation is increasingly becoming an appealing 
concept worth exploring by physiologists and oncologists. 
 
It is well established that cancer cells have increased glycolytic activity despite the 
nutritional status of their environment. In contrast, the human body is designed 
such, that when faced with decreased nutrient intake, the body is capable of 
mobilizing energy stores to its most vital organs to sustain homeostasis and 
function. Following digestion of a meal, 3-4 hours later, the body enters a post-
absorptive phase in which glycogenolysis occurs. During this process, the 
pancreas releases the hormone, glucagon, which stimulates the breakdown of 
glycogen stores in the liver thereby maintaining blood glucose levels. The early 
starvation phase occurs 24 hours after a meal and whilst glycogenolysis persists, 
the body activates an additional metabolic pathway to meet its energetic demands 
namely, gluconeogenesis. During gluconeogenesis adipose tissue is broken down, 
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and the glycerol back bone of fatty acids and amino acids are used to synthesize 
glucose. This phase persists until 60 hours of starvation is reached. At this point, 
all glucose stores have been depleted and thus the body resorts to activate 
ketogenesis in which the liver directs acetyl-CoA to synthesise ketone bodies. The 
brain being the most vital organ, adapts to use ketone bodies as its primary fuel 
through the synthesis of appropriate enzymes. Evidently, this is a well-orchestrated 
process of adaptation to nutritional deprivation (Hellerstein et al., 1997). 
 
In the context of cancer, one of the earliest studies was conducted in 1988 by 
Raffaghello and colleagues where normal and cancerous yeast cells were starved 
and then exposed to chemotherapy (unpublished). They found that normal cells 
survived the toxic dosage, but the cancer cells did not. These findings concluded 
that normal cells have a 'shield mode' - a kind of protective strategy that allows the 
organism to be resistant to not just one but various stresses, including starvation. 
This inspired an animal trial in which tumour bearing mice were starved for 48 
hours and then administered a high dose of chemotherapy. This study proved to be 
successful as 43% of the non-starved mice died, but only one of the starved mice. 
Once chemotherapy was terminated, a normal diet was resumed and the starved 
mice regained all the lost weight. With the great success of the animal trial, 
Raffaghello and colleagues proceeded with a human trial in 2010, in which ten 
patients starved from 48-140 hours prior to 5-56 hours after chemotherapy 
reported reduced side-effects of the toxic drug. 
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1.8 Motivation for this study 
 
Although extensive research has been done on human cancers, the role that 
starvation plays specifically in breast cancer in response to DXR-induced cell death 
remains to be elucidated.  Additionally, the duration of starvation in the studies 
conducted by Raffaghello et al. (2010) is extensive and some individuals may be 
unable to sustain such an extensive fast. It is thus imperative to explore this 
concept under shorter and more tolerable periods of starvation. For the purposes 
of this study we define starvation as the way in which the body responds to total 
nutrient deprivation.  
 
We hypothesise that short-term starvation will sensitize cancer cells to 
doxorubicin-induced cell death.  
 
In order to assess the hypothesis, this study was approached by four aims: 
1. To establish a time point at which MCF12A breast epithelial cells are 
protected against starvation.  
2. To determine the effect of short – term starvation on doxorubicin- induced 
cell death.  
3.  To assess autophagy in our experimental model. 
4. To assess these aims in an in vivo model of tumour bearing mice. 
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Chapter 2 – Materials and Methods 
2.1 Study Design (In vitro) 
 
Figure 2.1.1: Study Design: Human breast carcinoma cell line (MDA-MB-231) and human non-
tumourigenic mammary epithelial cell line (MCF12A) were subjected to: (1) various hours of 
starvation. (2) Depending on the results obtained at (1) these cell lines were used to conduct a MTT 
cell viability assay. (3) Only the cancer cells were further used for western blot analysis.  
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2.2 Cell culture 
 
Human non-tumourigenic mammary epithelial cell line (MCF12A) was obtained 
from the University of Cape Town and a human breast carcinoma cell line (MDA-
MB-231) was obtained from American Type Culture Collection (Rockville, MD, 
USA) which were maintained in a monolayer at 37°C and in a 21% O2, 5% CO2   
humidified air atmosphere of 95%. MDA-MB-231 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma Chemical Co., St Louis, MO, USA)  
supplemented with 10% foetal bovine serum (FBS) (Sigma Chemical Co., St Louis, 
MO, USA) and 1% penicillin/streptomycin (PenStrep) (Sigma Chemical Co., St 
Louis, MO, USA). The MCF12A growth medium contained a combination of 
Dulbecco’s modified Eagle’s medium (DMEM) and Nutrient Ham’s-F12 medium 
without phenol red (1:1) (Sigma Chemical Co., St Louis, MO, USA) and was 
supplemented with 10% foetal bovine serum (FBS), 1% PenStrep, 20 ng/ml 
epidermal growth factor (EGF) (Sigma Chemical Co., St Louis, MO, USA), 100 
ng/ml cholera toxin (Sigma Chemical Co., St Louis, MO, USA), 10 µg/ml insulin 
(Coetzenburg Campus Pharmacy) and 500 ng/ml hydrocortisone (Sigma Chemical 
Co., St Louis, MO, USA). Cells were allowed to proliferate in T75 flasks (75 cm2 
flasks, Greiner Bio One, Germany) over a period of three days with changing of 
fresh growth medium after every 24 hours. When cultures reached 80% confluency 
(Figure 2.2.1), they were passaged. Cells were then rinsed with phosphate 
buffered saline (PBS) and trypsinised (0.25% Trypsin-ethylene-diaminetetra-acetic 
acid (EDTA) (Invitrogen, Life Technologies) with gentle agitation to ensure 
Stellenbosch University  http://scholar.sun.ac.za
42 
 
complete detachment, following centrifugation at 200 g for 3 minutes. After cells 
were counted, cells were seeded at the appropriate density in fresh warm growth 
medium and plated in either 6 well plates (Greiner Bio One) or T25 flasks (25 cm2 
flasks, Greiner Bio One, Germany). 
 
2.3 Experimental protocol 
 
2.3.1 Treatment 
Upon treatment, growth medium was removed and replaced with fresh growth 
medium. Additionally, cells were washed twice with warm PBS to ensure removal 
of all debris and non-viable cells. Initially, to induce starvation, cells were incubated 
for 3, 6, 12, 24 and 48 hours in Hank’s Balanced Salt Solution (HBSS) (Sigma 
Chemical Co., St Louis, MO, USA), in order to establish a time point at which cells 
respond to starvation. Once a time point of 3 hours was established, four treatment 
groups were used: (1): control; (2): 5 µM of doxorubicin (DXR) for 24 hours; (3): 
short-term starvation (3 hours) (STS) and (4): short-term starvation (3 hours) prior 
to 24 hours treatment with doxorubicin (STS+ DXR). For complete treatment 
protocol, see Appendix A. 
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2.4 Cell Viability Analysis 
 
2.4.1 Trypan blue cell exclusion technique 
Following the termination of treatment, growth medium was removed and cells 
were washed with warm PBS, trypsinised and centrifuged. The supernatant was 
removed and the pellet re-suspended in 1 ml of PBS. From this cell suspension 10 
µl was removed and added to 10 µl of a 0.3%Trypan Blue dye (Invitrogen) and 
gently agitated. Of this solution, 10 µl was added to a two chambered cell counting 
slide (Invitrogen). An automatic cell counter (Invitrogen) was then employed to 
count the total number of viable cells. Trypan Blue cell exclusion technique is 
based upon the unique properties of the chromophores present in this vital dye. 
The chromophores are negatively charged, thus only interact with cells that have 
damaged membranes (staining blue). Thus, all cells which are viable exclude the 
dye. This technique was conducted in triplicate and three independent experiments 
were performed. Data was expressed as a percentage of the control, which was 
normalized to 100%. A detailed protocol is provided in appendix A. 
 
2.4.2 MTT Cell Viability Assay 
The MTT cell viability assay is based on the principal of MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) a yellow salt 
which is reduced to purple formazan crystals by enzymes in the cytoplasm and in 
the mitochondria of viable cells. This reductive capacity is dependent on active 
mitochondrial reductase enzymes (dehydrogenases), thus the conversion can be 
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directly correlated to the number of viable cells when assessed 
spectrophotometrically. Mitochondrial dehydrogenases of viable cells cleave the 
tetrazolium ring, yielding purple MTT formazan crystals which are insoluble in 
aqueous solutions. Acidified solutions such as the Isopropanol/Triton X solution 
can be used to dissolve the purple crystals. 
 
After the termination of the treatment, the medium was removed from each well of 
a 6 well plate and 1.5 ml PBS plus 500 μl MTT (0.01 g/ml) solution was added to 
each well and incubated at 37ºC for 1 hour. After 1 hour incubation period, if cells 
were detached, the content was transferred to eppendorf tubes and centrifuged for 
2 min at 1000 rpm. The supernatant was decanted and 2 ml of hydrogen chloride-
isopropanol/Triton (1% HCl in isopropanol; 0.1% Triton X-100; 50:1) solution was 
added to each pellet and re-suspended. Some cells remained attached, thus the 
re-suspension was added back to the original plates and 2 ml HCl-
isopropanol/Triton X solution was added to each well, covered with silver foil and 
gently agitated at 37ºC for  5 minutes to dissolve the purple crystals formed. The 
content of each well was then transferred to a 2 ml cuvette. The optical density 
(OD) was determined spectrophotometrically (Cecil-CE 2021-2000 Series, Lasec) 
at a wavelength of 540 nm, using HCl-isopropanol/Triton X solution as the blank. 
All values obtained from treated groups were expressed as a percentage of the 
control values. A detailed protocol is provided in appendix A. 
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2.4.3 Caspase-Glo®3/7 Assay 
The Caspase-Glo® 3/7 assay kit (Promega, G8091) provides a reagent containing 
a luminogenic caspase-3/7 substrate, which is optimized for caspase and 
luciferase activity. Addition of the reagent to cells results in caspase mediated 
cleavage of the substrate, followed by the release of amino-luciferin (a substrate 
for luciferase) which generates a luminescent signal. Luminescence is proportional 
to the amount of caspase activity present in the sample.  MDA-MB-231 and MCF-
12A cells were grown and treated, as previously stated, in 96-well luminometer 
white plates. Caspase-3/7 reagent was added to each well (100 μl) and incubated 
for 1 hour at room temperature. Immediately after incubation, luminescence was 
measured using a luminometer (GLOMAX 96 microplate Luminometer, Promega). 
A detailed protocol is provided in appendix A. 
. 
2.5 Western Blots  
 
2.5.1 Protein extraction and cell lysate preparation  
 
Cells were washed thoroughly with PBS after which T25 flasks were placed on ice. 
This was followed by the addition of 2 ml of ice cold radio-immunoprecipitation 
(RIPA) buffer, pH 7.4, containing (in mM): tri-(hydroxylmethyl)-aminomethane 
(TRIS)-HCl 50, NP-40 1%, Na-Deoxycholate 0.25%, EDTA (Ethylenediamine-tetra-
acetic acid) 1, sodium fluoride (NaF) 1, soybean trypsin inhibitor (SBTI) 4 μg/ml, 
phenyl-methyl-sulphonyl fluoride (PMSF) 1, Benzamidine 1, leupeptin 1 μg/ml and 
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Triton X-100. Whilst remaining on ice, cells were scraped free from flasks and 
transferred to eppendorf tubes placed on ice. Cells were then sonicated (Ultrasonic 
Liquid Processor, Qsonica) for ± 20 seconds to ensure the release of proteins and 
centrifuged (5900 g at 4ºC for 10 min) to remove nuclei and cellular debris. Lysates 
were either stored at -80˚C or protein content was quantified using Bradford protein 
determination method (Bradford, 1976), followed by immediate preparation of cell 
lysates. Laemmli sample buffer containing (in M): 33.3 ml TRIS 0.5, pH 6.8, 
10%SDS, 2.5 ml glycerol, 0.2 ml 0.5% bromophenol blue in deionized water was 
used to prepare cell lysates. A combination of 850 μl sample buffer and 150 μl 
mercaptoethanol was vortexed and the appropriate amounts according to 
calculations were accurately aliquoted to each protein sample (20 μg). Samples 
were boiled for 5 min at 95˚C before being spun shortly in a microcentrifuge. 
 
2.5.2 Sodium-dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS- 
         PAGE) and Western blot analysis 
Total protein lysates (20 μg) were loaded and separated using gradient gels ( 4% - 
15%) sodium-dodecyl-sulphate poly-acrylamide gel electrophoresis(SDS-PAGE) 
and a 4% stacking gel (Bio-Rad Mini-Protean ® TGX ™ Precast Gels). A pre- 
stained protein marker ladder (peqGOLD, PEQLAB Biotechnologie GMBH, 
Germany) was loaded in the first lane on each gel for determination of molecular 
weights of specific bands. Proteins were separated on gels at 150 V (constant) and 
400 mA for 60 minutes (Mini- PROTEAN Tetra Tank, Bio-Rad, USA). Following, 
SDS- PAGE, proteins were transferred to a polyvinylidine fluoride (PVDF) 
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membrane (Bio-Rad Trans-Blot Turbo Transfer packs) using  the Bio-Rad electro-
transfer system (Bio-Rad Trans- Blot Transfer System) for 12 minutes at 150V and 
1.5 A. Non-specific binding sites were blocked with 5% fat-free milk in TRIS-
buffered saline-Tween (TBS-T) and membranes were incubated overnight with the 
primary antibodies (cleaved-caspase-3, cleaved- PARP, p62/SQSTM1, LC-3, 
phosphor-AMPK-α, phopho-mTOR and  β-Actin). Membranes were then washed 
with TBS-T (3 x 5 min) and the primary antibody was conjugated by the addition of 
a diluted horseradish peroxidase-labelled secondary antibody (Amersham LIFE 
SCIENCE) for 1 hour at room temperature. Thereafter, membranes were 
thoroughly washed before being exposed to ECL (chemi-luminescent reagent) for 
1 minute. Bands were then detected using the Bio-Rad Chemi-Doc system. 
Exposed bands were visualised and quantified using densitometry software 
(Quantity1). All bands were expressed as optical density readings relative to a 
control present on the same blot. 
 
In this study, western blot procedure was performed in the following manner.  Cells 
were treated as previously described and at the end of treatment, harvested. Three 
independent experiments were performed (n=3). Each experiment consists of the 
four experimental groups and samples were loaded on the gel as follows: lane 1: 
protein ladder, lane 2: control, lane 3: doxorubicin, lane 4 starvation and lane 5: 
doxorubicin + starvation. Twelve well gradient gels (4-15%) were used throughout 
the study.  We used western blot analysis to examine the following proteins: 
cleaved caspase-3 (17-19 kDa) and cleaved-PARP (89 kDa); LC3 I and II (16-18 
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kDa) and p62 (62 kDa) as well as phospho-AMPK (62 kDa) and phospho-mTOR 
(289 kDa). The membranes were cut or stripped to visualise all proteins mentioned 
above for each experiment. Thereafter the membranes were probed with β-actin to 
ensure equal loading of proteins.  Membranes were then washed with TBS-T (3 x 5 
min) and the primary antibody was conjugated by the addition of a diluted 
horseradish peroxidase-labelled secondary antibody (Amersham LIFE SCIENCE) 
for 1 hour at room temperature. Thereafter, membranes were thoroughly washed 
before being exposed to ECL (chemi-luminescent reagent) for 1 minute. Bands 
were then detected using the Bio-Rad Chemi-Doc system. Exposed bands were 
visualised and quantified using densitometry software (Quantity1). Each 
experimental group on a membrane was normalised to its corresponding β-actin 
band. Thereafter, the averages of all experimental groups (control, doxorubicin, 
starvation and dox+starvation) (n=3) were normalised to the control which was set 
as one.  
 
2.6 Live Cell Imaging 
 
 
This technique offers a dynamic approach to monitor over time the various 
morphological changes, localisation and distribution of organelles within cells after 
treatment. For Live Cell Imaging, MDA-MB-231 cells were seeded in 8-chamber 
dishes with a density of 2x104 cells and maintained at 37°C and in a 21% O2, 5% 
CO2   humidified air atmosphere of 95%, in growth medium. Once confluent, cells 
were treated as previously described and stained accordingly. Image acquisition 
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was performed on an Olympus Cell^R system attached to an IX 81 inverted 
fluorescence microscope equipped with an F-view-II cooled CCD camera (Soft 
Imaging Systems). Using a Xenon-Arc burner (Olympus Biosystems GMBH) as 
light source, images were acquired, using GFP excitation and emission settings, as 
well as the UGB triple band pass emission filter cube. 
 
2.6.1 GFP- LC3 Transfection 
 
LC3 (microtubule- associated protein 1 light chain 3) is recruited to the 
autophagosomal membrane, in response to nutrient starvation during autophagy 
(Mizushimi, 2004).  Thus, the green fluorescent protein (GFP) - tagged 
microtubule-associated protein 1 light chain 3 (LC3)-expressing cells may be used 
to demonstrate the induction of autophagy. GFP- LC3 transfected cells produce a 
scattered pattern of distribution under control conditions, in comparison to a 
punctuate pattern of GFP-LC3 expression (GFP-LC3 dots) when induced by 
autophagy (Kanzawa et al., 2004). Prior to transfection, media was removed and 
cells were washed with warm PBS. Transfection was performed using 800 ng of 
plasmid DNA concentration for LC3 which was prepared with 50 µl serum free 
media by the addition of a solution containing 200 µl serum free media and 12 µl of 
lipofectamin. After vortexing for 20 minutes at room temperature this reagent 
mixture was added to each chamber (Kindly provided by Dr B. Loos, University of 
Stellenbosch, South Africa). Lipofectamin is a chemical transfection agent. This is 
a process of transient transfection as only few cells may take up the plasmid 
construct and thus express the protein in a non-stable fashion. Therefore, cells do 
Stellenbosch University  http://scholar.sun.ac.za
50 
 
not express the protein for long periods of time as the plasmid is released during 
cell cycle progression or after a few divisions. 
 
2.6.2 Fluorescent Staining: Morphological Analysis of Cell Death and  
         Mitochondria 
To assess cell death, cells were stained with Hoechst 33342 (in a 1:200 dilution in 
PBS) (Sigma, B2261). Hoechst intercalates with DNA of all cells however; 
apoptotic cells are characterised by nuclear fragmentation (karyorrhexis) and 
nuclear condensation (pyknosis) (Kerr, 1994) and exhibit a greater intensity of the 
fluorescent signal emitted. Hoechst was added onto the cells at a final 
concentration of 50 μg/ml, and incubated for 10 min. Cells were classified 
according to their nuclear signal: (i) normal nuclei with blue chromatin, showing 
organization with a distribution of heterochromatin and euchromatin and (ii) cells 
displaying bright blue and substantially condensed or fragmented nuclei indicative 
of apoptosis. Together with Hoechst 33342, the cell-permeant, MitoTracker ® Red 
(Molecular Probes, M-7512) was added directly to the cells at a final concentration 
of 25 nM. This fluorescent probe contains a mildly thiol-reactive chloro-methyl 
moiety specific for mitochondrial labelling and maybe used to visualise localisation 
and morphology of mitochondria. Staining mitochondria only in viable cells, its 
accumulation is dependent upon membrane potential. Using the Olympus Cell^R 
Soft Imaging Systems, images of three random selected fields of view were 
acquired immediately thereafter, using 572 excitation and UBG emission filters. 
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2.7 Statistical analysis 
Values are expressed as mean ± standard error of the mean (SEM). Data were 
analysed using a one-way analysis of variance (ANOVA) with Bonferroni’s Multiple 
Comparison as a post-hoc test. P<0.05 was considered as statistically significant. 
 
2.8 Study Design (In vivo) 
 
 
Figure 2.8.1: In vivo experimental protocol. Tumours were allowed to grow for 21 days and mice 
were subjected thereafter to the above treatment protocol. 
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2.9 Cell culture of E0771 mouse mammary cancer cells 
 
Experiments were conducted using the murine metastatic mammary 
adenocarcinoma cell line E0771 provided by Fengzhi Li (Rosswel Park Cancer 
Institute, Buffalo, New York, USA). Cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Sigma Chemical Co., St Louis, MO, USA) supplemented 
with 10% foetal bovine serum (FBS) (Sigma Chemical Co., St Louis, MO, USA) 
and 1% penicillin/streptomycin (PenStrep) (Sigma Chemical Co., St Louis, MO, 
USA). Cells were allowed to proliferate in T75 flasks (75 cm2 flasks, Greiner Bio 
One, Germany) over a period of two days with changing of fresh growth medium 
after every 24 hours. When cultures reached 80% confluence (Figure 2.9.1), they 
were split equally into 3 other T75 flasks in order to yield a sufficient amount of 
cells for inoculation. Splitting was achieved by rinsing cells with warm, sterile 
phosphate buffered saline (PBS) and trypsinising the cells (0.25% Trypsin – 
ethylene diaminetetra-acetic acid (EDTA) (Invitrogen, Life Technologies) with 
occasional gentle agitation to ensure complete detachment, following centrifugation 
at 200 g for 3 minutes. Experiments were conducted using exponentially growing 
cells. 
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Figure 2.9.1: Breast cancer mouse cell line E0771, showed at 80% confluence, under 20X and 40X 
magnification. 
 
2.10 Animal Protocols and tumour establishment 
 
All animal protocols were carried out according to the guideline for the care and 
use of laboratory animals implemented at Stellenbosch University.  Institutional and 
international ethical guidelines were applied with respect to the handling of the 
experimental animals. Six week old C57BL6 mice (Stellenbosch University animal 
facility) were used for the purposes of this study. Mice were maintained on a 
standard diet and tap water ad libitum before being subjected to the experimental 
protocol. The protocol used was adapted from Ewens et al (2006). Mice were 
inoculated subcutaneously on the left pad of the fourth mammary gland with 200 µl 
of 2.5x105 E0771 cells suspended in Hanks Balanced Salt Solution, using a 23-
gauge needle.  Mice were weighed and inoculated with E0771 cell suspensions on 
day 0 and small tumours were evident by days 11-14. Tumours were allowed to 
grow further until day 21, when medium to large size tumours were visible. Tumour 
sizes were monitored every second day by taking measurements in two 
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perpendicular dimensions parallel to the ventricular surface of the mice using a 
digital calliper (tumour volume = length x width). The body weight was monitored 
twice weekly. On day 20, mice were distributed among four groups which included 
a Control group, DXR treated group, Starvation group and a combination group of 
prior starvation following DXR treatment (Figure 2.10.1). Additionally, mice in each 
group were labelled by ear clipping procedure. Administration of treatment 
occurred on the days indicated in Figure 2.10.1. The Doxorubicin group received a 
total of two injections (5 mg/kg, intra-peritoneal) as described by Zhu et al (2009) 
for 1 week. Briefly, 5 mg/kg doxorubicin was administered at 2 day intervals with an 
accumulative dose of 10 mg/kg. The Starvation group was subjected to 24 hours of 
starvation (removal of standard chow diet). For the Starvation and DXR, mice were 
subjected to 24 hours of starvation before receiving a 5 mg/kg DXR injection. Upon 
termination of the experimental protocol, mice were killed and tumours excised. 
The tumours appeared to be homogenous by macroscopic examination and were 
vascularised with no apparent hypoxic regions. Therefore, the whole tumour was 
excised and cut into three equal parts. Samples were placed in eppendorf tubes 
and exposed to liquid nitrogen before being placed in a -80 freezer for future 
experimental analysis. Prior to protein extraction, samples were submitted to 
further tissue homogenization and sonification protocols (see appendix A). 
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Figure 2.10.1: In vivo experimental groups utilised for the entire duration of this study. 
 
 
2.11 Western Blots 
 
 
2.11.1 Protein extraction and sample preparation  
 
Proteins in tumours were extracted with 1000 µl of ice cold 
radioimmunoprecipitation (RIPA) buffer, pH 7.4, containing (in mM): tri-
(hydroxylmethyl)-aminomethane (TRIS)-HCl 50, NP-40 1%, Na-Deoxycholate 
0.25%, EDTA (Ethylenediamine-tetra-acetic acid) 1, sodium fluoride (NaF) 1, 
soybean trypsin inhibitor (SBTI) 4 μg/ml, phenyl-methyl-sulphonyl fluoride (PMSF) 
1, Benzamidine 1, leupeptin 1μg/ml and Triton X-100. Tumour tissue samples were 
then sonicated (Ultrasonic Liquid Processor, Qsonica) for ± 5 mins to ensure the 
release of proteins and centrifuged (5900 g at 4ºC for 10 min) to remove nuclei and 
cellular debris. Samples were either stored at -80˚C or protein content was 
quantified using Bradford protein determination method (Bradford, 1976), followed 
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by immediate preparation of tissues samples. Laemmli sample buffer containing: 
33.3 ml TRIS 0.5, pH 6.8, 10% SDS, 2.5 ml glycerol, 0.2 ml 0.5% bromophenol 
blue in deionized water was used to prepare cell samples. A combination of 850 μl 
sample buffer and 150 μl mercaptoethanol was vortexed and the appropriate 
amounts according to calculations were accurately aliquoted to each protein 
sample (20 μg). Samples were boiled for 5 min at 95˚C before being spun for 5 
mins in a microcentrifuge. 
 
2.11.2 Sodium-dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS-                                               
 PAGE) and Western blot analysis 
Total protein lysates (20 μg) were loaded and separated using gradient gels ( 4% - 
15%) sodium-dodecyl-sulphate-poly-acrylamide gel electrophoresis(SDS-PAGE) 
and a 4% stacking gel (Bio-Rad Mini-Protean ® TGX ™ Precast Gels). A pre- 
stained protein marker ladder (peqGOLD, PEQLAB Biotechnologie GMBH, 
Germany) was loaded in the first lane on each gel for determination of molecular 
weights of specific bands. Gels were run at 150 V (constant) and 400 mA for 60 
minutes (Mini- PROTEAN Tetra Tank, Bio-Rad, USA). Following, SDS- PAGE, 
proteins were transferred to polyvinylidine fluoride (PVDF) membrane (Bio-Rad 
Trans-Blot Turbo Transfer packs) using  the Bio-Rad electro-transfer system (Bio-
Rad Trans- Blot Transfer System) for 12 minutes at 150V and 1.5 A. Non-specific 
binding sites were blocked with 5% fat-free milk in TRIS-buffered saline-Tween 
(TBS-T) and membranes were incubated overnight with the primary antibodies 
(cleaved-caspase-3, cleaved-PARP, p62/SQSTM1, LC-3, phosphor-AMPK-α, 
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phospho-mTOR and  β-Actin). In this part of the study, western blot procedure was 
performed in the following manner:  Animals were treated as previously described 
and at the end of the treatment; tissue was obtained as previously described. 
Although there were initially at least six animals per group, some animals died 
before the termination of the experiment. These tumours were not used for western 
blotting, however, at least three animals remained in each group and their tumours 
were analysed. The samples were loaded on the gel as follows: lane 1: protein 
ladder, lane 2: control, lane 3: doxorubicin, lane 4 starvation and lane 5: 
doxorubicin + starvation. Fifteen well gradient gels (4-15%) were used throughout 
this part of the study.  We used western blot analysis to examine the following 
proteins; cleaved caspase-3 (17-19 kDa) and cleaved-PARP (89 kDa); LC3 I and II 
(16-18 kDa) and p62 (62 kDa) as well as phospho-AMPK (62 kDa) and phospho-
mTOR (289 kDa). The membranes were cut or stripped to visualise all proteins 
mentioned above for each experiment. Thereafter the membranes were probed 
with β-actin to ensure equal loading of proteins.  Membranes were then washed 
with TBS-T (3 x 5 min) and the primary antibody was conjugated by the addition of 
a diluted horseradish peroxidase-labelled secondary antibody (Amersham LIFE 
SCIENCE) for 1 hour at room temperature. Thereafter, membranes were 
thoroughly washed before being exposed to ECL (chemi-luminescent reagent) for 
1 minute. Bands were detected using the Bio-Rad Chemi-Doc system. Exposed 
bands were visualised and quantified using densitometry software (Quantity1). All 
bands were expressed as optical density readings relative to a control present on 
the same blot. Membranes were then washed with TBS-T (3 x 5 min) and the 
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primary antibody was conjugated by the addition of a diluted horseradish 
peroxidase-labelled secondary antibody (Amersham LIFE SCIENCE) for 1 hour at 
room temperature. Thereafter, membranes were thoroughly washed before being 
exposed to ECL (chemi-luminescent reagent) for 1 minute. Bands were then 
detected using the Bio-Rad Chemi-Doc system. Exposed bands were visualised 
and quantified using densitometry software (Quantity1). Each experimental group 
on a membrane was normalised to its corresponding β-actin band. Thereafter, the 
averages of all experimental groups (control, doxorubicin, starvation and 
dox+starvation) (n=3) were normalised to the control which was set as one.  
 
2.12 Statistical analysis 
 
Values are expressed as mean ± standard error of the mean (SEM). Data were 
analysed using a one-way analysis of variance (ANOVA) with Bonferroni’s Multiple 
Comparison as a post-hoc test. P<0.05 was considered as statistically significant. 
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Chapter 3 - Results 
IN VITRO 
3.1 The effect of various hours of starvation on cell viability and    
cell death 
 
To establish a time point at which MCF12A breast epithelial cells are protected 
against starvation. Both cells lines were subjected to 0, 3, 6, 12, 24 and 48 
hours of starvation in Hanks Balanced Salt Solution and cell viability was 
assessed using the MTT assay and the trypan blue assay. This was followed by 
a Caspase-Glo 3/7 assay to determine if programmed cell death was involved 
during short-term starvation. 
 
MDAMB231 cells showed a significant decrease in cell viability following 48 
hours of incubation in nutrient deprived media (HBSS) when compared to the 
control (9.364 ± 2.126% vs 100%, p < 0.0001) (Figure 3.1.1 A). In contrast to 
this observation, the viability of MCF12A cells significantly decreased following 
6, 24 and 48 hours of starvation when compared to the control. However, no 
significant changes in cell viability were observed following 3 and 12 hours of 
starvation when compared to the control (Figure 3.1.1 B). 
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Figure 3.1.1: The effect of various hours of starvation on the viability of MDAMB231 breast 
cancer cells (Bar graph A) and MCF12A non-tumourigenic breast epithelial cells (Bar graph B). 
MDAMB231 and MCF12A cells were incubated in Hanks Balanced Salt Solution for 0 (Control), 
3, 6, 12, 24 and 48 hours. Cell viability was assessed using the MTT Assay. Values are 
expressed as percentage of the control and presented as means ± SEM (n=3), A: ***p < 0.0001 
vs 0 hrs. B: **p < 0.001 vs 0 hrs, ***p<0.0001 vs 0 hrs.  Abbreviations- hr: hours. 
 
 
MDAMB231 cells showed a significant decrease in cell viability following 48 
hours of incubation in nutrient deprived media when compared to the control 
(5.889 ± 1.852% vs 100%, p < 0.0001) (Figure 3.1.2 A). The viability of 
MCF12A cells demonstrated no significant changes following 3 hours of 
starvation in comparison to the control, however viability decreased following 6, 
12, 24 and 48 hours of nutrient deprivation (Figure 3.1.2 B). 
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Figure 3.1.2: The effect of various hours of starvation on the viability of MDAMB231 breast 
cancer cells (Bar graph A) and MCF12A non-tumourigenic breast epithelial cells (Bar graph B). 
MDAMB231 and MCF12A cells were incubated in Hanks Balanced Salt Solution for 0 (Control), 
3, 6, 12, 24 and 48 hours. Cell viability was assessed using the trypan blue assay. Values are 
expressed as percentage of the control and presented as means ± SEM (n=3), A: *p < 0.05 vs 0 
hrs, ***p < 0.0001 vs 0 hrs. B: **p < 0.001 vs 0 hrs, ***p<0.0001 vs 0 hrs. Abbreviations- hr: 
hours. 
 
 
MDAMB231 cells displayed a significant increase in caspase 3/7 activity in 
response to 48 hours of starvation when compared to the control (8.346 ± 1.620 
fold vs 1.000 ± 0.000 fold, p < 0.0001) (Figure 3.1.3 A). MCF12A cells showed 
no significant changes in caspase 3/7 activity following 3 hours of starvation. 
However, a significant decrease in caspase3/7 activity was detected when cells 
were starved for 12 hours when compared to the control (0.169 ± 0.039 fold vs 
1.000 ± 0.013 fold, p < 0.0001) (Figure 3.1.3 B). 
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Figure 3.1.3: The effect of various hours of starvation on programmed cell death in MDAMB231 
breast cancer cells (Bar graph A) and MCF12A non- tumourigenic breast epithelial cells (Bar 
graph B).Programmed cell death was assessed using the Caspase-Glo® 3/7 Assay. Caspase 
3/7 activity was taken to be proportionate to the produced luminescence intensity per sample. 
Results represent the fold change in luminescence and presented as means ± SEM (n=3), A: *p 
< 0.0001 vs 0 hrs. B: **p < 0.001 vs 0 hrs, ***p < 0.0001 vs 0 hrs. Abbreviations- hr:hours; AU: 
Arbitrary Units. 
 
3.2 The effect of short-term starvation on doxorubicin-induced  
cell death 
 
Based on the results obtained in our preliminary study, 3 hours of starvation 
was chosen for future in vitro experiments since no significant changes in cell 
viability or increase in apoptosis occurred at this time-point in the normal 
MCF12A breast epithelial cells. The following four treatment groups were used 
in this study: (1): control; (2): 5 µM of doxorubicin (DXR) for 24 hours; (3): short-
term starvation (3 hours) (STS) and (4): short- term starvation (3 hours) prior to 
24 hours treatment with doxorubicin (STS+ DXR). 
 
The MTT Assay was first used to assess cell viability in both MDAMB231 
cancer cells and MCF12A breast epithelial cells. MDAMB231 cells starved for 3 
hours and treated with DXR for 24 hours showed a significant decrease in cell 
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viability when compared to the DXR treated group only (59.91 ± 4.208% vs 
71.16 ± 2.490%, p < 0.05) (Figure 3.2.1A). In contrast, MCF12A cells starved 
for 3 hours and treated with DXR for 24 hours were protected by starvation as 
the cell viability significantly increased when compared to the DXR treated 
group only (93.36 ± 5.406% vs 73.55 ± 7.197%, p < 0.05) (Figure 3.2.1 B). 
 
Figure 3.2.1: The effect of short-term starvation on doxorubicin-induced cell death. MDAMB231 
breast cancer cells (Bar graph A) and MCF12A non-tumourigenic breast epithelial cells (Bar 
graph B) were subjected to the following conditions: (1) control; (2) 5 µM DXR; (3) 3 hours 
starvation and (4) starvation with DXR. Cell viability was assessed using MTT Assay. Values 
are expressed as percentage of the control and presented as means ± SEM (n=3), A: ***p < 
0.0001 vs control, *p < 0.05 vs DXR.  B: **p < 0.001 vs control, *p < 0.05 vs DXR. 
Abbreviations- DXR: Doxorubicin; STS: Short-term starvation. 
 
 
 
To provide further insight into programmed cell death and the mechanisms that 
are involved, MDAMB231 breast cancer cells were analysed using recognized 
markers for programmed cell death, namely cleaved caspase-3 and cleaved-
PARP. The presence of these markers was quantified using western blot 
analysis to indicate the response of the treated groups to apoptotic stimuli. 
MDAMB231 cells showed a significant increase in caspase-3 cleavage in 
response to DXR when compared to the control (2.376 ± 0.1022 fold vs 1.000 ± 
0.000 fold, p < 0.0001). A further increase in caspase-3 cleavage was observed 
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with STS+DXR when compared to the DXR treated group (2.376 ± 0.1022 fold 
vs 1.991 ± 0.0794 fold, p < 0.05) (Figure 3.2.2 A). Confirming this increase in 
apoptotic activity, PARP cleavage was significantly increased in response to 
STS+DXR in comparison to the DXR (1.939 ± 0.201 fold vs 0.236 ± 0.089 fold, 
p < 0.05) (Figure 3.2.2 B). 
Figure 3.2.2: The effect of short-term starvation on doxorubicin-induced apoptotic cell death. 
MDAMB231 breast cancer cells were subjected to the following conditions: (1) control; (2) 5 µM 
DXR; (3) 3 hours starvation and (4) starvation with DXR. Apoptotic cell death was measured 
using western blot analysis. Bar graphs show: A) Cleaved caspase-3 and B) Cleaved-PARP 
protein levels (normalized to β-actin vs control). Values are expressed as means ± SEM (n=3), 
A: ***p < 0.0001 vs control,*p < 0.05 vs DXR. B: *p < 0.05 vs DXR. Abbreviations- DXR: 
Doxorubicin; STS: Short-term starvation; AU: Arbitrary Units. A representative blot is shown. 
 
 
 
3.3 The effect of short-term starvation and doxorubicin 
treatment on autophagic activity 
 
LC3 and p62/SQSTM1 as markers of autophagic activity were assessed by 
western blotting. LC3 II examination revealed high basal levels of autophagy in 
the control group. This significantly decreased with DXR treatment (0.634 ± 
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0.0147 fold vs 1.000 ± 0.000 fold, p < 0.001) and STS (0.248 ± 0.090 fold vs 
1.000 ± 0.000 fold, p < 0.0001) when compared to the control. A further 
decrease was observed with STS+DXR (0.128 ± 0.003 fold vs 0.634 ± 0.0147 
fold, p < 0.0001) when compared to the DXR (Figure 3.3.1 A). 
 
p62, a poly-ubiquitin protein degraded by autophagy is inversely proportional to 
the extent of autophagic activity. However, the presence of DXR significantly 
decreased p62 (0.519 ± 0.443 fold vs 1.000 ± 0.000 fold, p < 0.001) when 
compared to the control. A significant increase was observed with STS+DXR 
(2.524 ± 0.131 fold vs 0.519 ± 0.443 fold, p < 0.0001) when compared to DXR 
treatment only (Figure 3.3.1 B). 
 
 
Figure 3.3.1: The effect of short-term starvation and doxorubicin treatment on autophagic 
activity. MDAMB231 breast cancer cells were subjected to the following conditions: (1) control; 
(2) 5 µM DXR; (3) 3 hours starvation and (4) starvation with DXR. Autophagic activity was 
measured using western blot analysis. Bar graphs show: A) LC3 II and B) p62/SQSTM1 protein 
levels (normalized to β-actin vs control). Values are expressed as means ± SEM (n=3), A: **p < 
0.001 vs control, ***p < 0.0001 vs control ###p < 0.0001 vs DXR. B: **p < 0.001 vs control, ***p < 
0.0001 vs DXR. Abbreviations- DXR: Doxorubicin; STS: Short-term starvation; AU: Arbitrary 
Units. A representative blot is shown. 
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3.4 The effect of short-term starvation and doxorubicin 
treatment on p-AMPK (oxygen sensor) and p-mTOR 
(energy sensor) 
 
Figure 3.4.1: The effect of short-term starvation and doxorubicin treatment on p-AMPK and p-
mTOR. MDAMB231 breast cancer cells were subjected to the following conditions: (1) control; 
(2) 5 µM DXR; (3) 3 hours starvation and (4) starvation with DXR. Markers for AMPK and mTOR 
were measured using western blot analysis. Bar graphs show: A) p-AMPK and B) p-mTOR 
protein levels (normalized to β-actin vs control). Values are expressed as means ± SEM (n=3), 
A: **p < 0.0001 vs control. B:  ***p < 0.0001 vs control, ###p < 0.0001 vs DXR. Abbreviations- 
DXR: Doxorubicin; STS: Short-term starvation; AU: Arbitrary Units. A representative blot is 
shown. 
 
 
Phospho-AMPK-α (p-AMPK) and phospho-mTOR (p-mTOR) as an oxygen and 
energy sensor respectively, were assessed by western blotting. AMPK 
phosphorylation was significantly higher in the STS treated group when 
compared to the control (21.90 ± 3.530 fold vs 1.000 ± 0.000 fold, p < 0.001) 
(Figure 3.4.1 A). STS also increased p-mTOR activity significantly when 
compared to the control (0.226 ± 0.021 fold vs 1.000 ± 0.000 fold, p < 0.0001). 
Furthermore, p-mTOR activity with STS+DXR significantly decreased (0.349 ± 
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0.043 fold vs 0.946 ± 0.091 fold, p < 0.0001) when compared to DXR (Figure 
3.4.1B). In addition, to visually confirm apoptotic and autophagic activity as well 
as mitochondrial membrane integrity, MDAMB231 cells were transfected with 
GFP-LC3 and stained with Hoechst 3422 and MitoTracker Red and visualized 
using Live Cell Imaging.  
 
Mitochondrial integrity was maintained when cells were starved for 3 hours and 
in the control. However, when cells were treated with DXR, this induced severe 
damage to the mitochondrial membranes. GFP- LC3 transfected cells produce 
a scattered pattern of distribution of autophagic vacuoles under control 
conditions (Figure 3.42), in comparison to a punctuate pattern of GFP-LC3 
expression (GFP-LC3 dots) when induced by autophagy (Kanzawa et al., 2004) 
as visualized in the STS and STS+DXR treated groups.  
 
Additionally, Hoechst binds to DNA of all cells however; apoptotic cells are 
characterized by nuclear fragmentation and nuclear condensation (Kerr, 1994) 
and exhibit a greater intensity of the dye as observed in the DXR, STS and 
STS+DXR groups. Observations are indicated by yellow arrows in Figure 3.42.  
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Figure: 3.4.2: Effects of various treatment regimens on mitochondrial integrity, apoptotic cell 
death and formation of autophagic vacuoles. MDAMB231 cells were transfected with GFP-LC3 
and stained with Hoechst 33342 and MitoTracker Red and visualized using Live Cell Imaging. 
Yellow Arrows indicate: presence of autophagic vacuoles (green), changes in mitochondrial 
integrity (red) and DNA fragmentation and membrane blebbing (blue) in the various groups. 
Abbreviations- C: Control; DXR: Doxorubicin; STS: Short-term starvation.  
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In vivo 
3.5 The effect of various treatments on tumour growth 
In the in vivo section of this study, C57BL6 tumour-bearing mice were 
distributed among four groups which included a Control group, DXR treated 
group, 24 hour starvation group and a combination group of 24 hours starvation 
prior to DXR treatment. Tumour size was measured every second day as 
described previously. Due to difficulty in accessibility of the tumour to obtain 
parameters of length and width in all tumours, no SEM or multiple comparisons 
were performed, hence the obtained values merely represent averages 
between groups. The following trends were however observed; a decrease in 
tumour volume was observed in the DXR-group when compared to the control. 
A similar response was observed in the combination of starvation and DXR and 
in the starvation group (at a slower rate) where tumour volume also decreased 
when compared to the DXR treated group.  
 
Figure 3.5.1: The effect of different treatment regimens on tumour growth. Tumour size was 
assessed immediately after the occurrence of tumours (± 21 days after tumour cell inoculation) 
and throughout the study. Day 30 represents the last day tumour size was assessed before 
prior to intervention treatment was conducted. Animals were either treated with DXR (5 mg/kg) 
or starved for 24 hours or a combination of prior starvation following DXR treatment.  
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3.6 The effect of short-term starvation on doxorubicin-induced 
cell death in tumour bearing mice 
 
To provide further insight into programmed cell death and the mechanisms that 
are involved, tumour tissue from the various treated groups were analysed 
utilizing cleaved caspase-3 and cleaved-PARP as markers for apoptotic cell 
death. The presence of these markers in the above mentioned groups were 
quantified using western blot analysis. Tumour tissue analysis revealed a 
significant increase in caspase-3 cleavage in response to DXR (9.367 ± 0.626 
fold vs 1.000 ± 0.000 fold, p < 0.0001) and a significant decrease with STS 
(3.831 ± 0.025 fold vs 1.000 ± 0.000 fold, p < 0.001) when compared to the 
control. Additionally, treatment with STS+DXR significantly decreased when 
compared to DXR (6.916 ± 0.165 fold vs 9.367 ± 0.626 fold, p < 0.0001) 
(Figure: 3.6.1A). Subsequently, PARP cleavage was significantly increased in 
response to DXR treatment when compared to the control (17.61 ± 1.572 fold 
vs 1.000 ± 0.000 fold, p < 0.001) and significantly decreased with STS+DXR 
when compared to DXR (10.84 ± 0.490 fold vs 17.61 ± 1.572 fold, p < 0.0001) 
(Figure 3.6.1 B). 
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Figure 3.6.1: The effect of short-term starvation on doxorubicin-induced apoptotic cell death. 
Animals were either treated with DXR (5 mg/kg) or starved for 24 hours or a combination of 
prior starvation following DXR treatment. Apoptotic cell death was measured using western blot 
analysis. Bar graphs show: A) cleaved caspase-3 and B) cleaved-PARP protein levels 
(normalized to β-actin vs control). Values are expressed as means ± SEM (n=3), A: ***p < 
0.0001 vs control, **p < 0.001 vs control, ###p < 0.0001 vs DXR. B: ***p < 0.0001 vs control,**p < 
0.001 vs DXR. Abbreviations- DXR: Doxorubicin; STS: Short-term starvation; AU: Arbitrary 
Units. A representative blot is shown. 
 
 
3.7 The effect of short-term starvation and doxorubicin 
treatment on autophagic activity in tumour bearing mice 
 
LC3 and p62/SQSTM1 as markers of autophagic activity were assessed by 
western blotting. LC3 II examination was significantly higher in the DXR treated 
group when compared to the control (3.243 ± 0.378 fold vs 1.000 ± 0.000, p < 
0.0001) (Figure 3.7.1A). Since, p62/SQSTM1 is inversely proportional to the 
extent of autophagic activity, the presence of DXR significantly decreased p62 
when compared to control (0.329 ± 0.040 fold vs 1.000 ± 0.000 fold, p < 0.001). 
In contrast, STS+DXR significantly increased p62 expression in comparison to 
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the DXR treated group (0.822 ± 0.119 fold vs 0.329 ± 0.040 fold, p < 0.05) 
(Figure 3.7.1B).  
 
 
 
Figure 3.7.1: The effect of short-term starvation and doxorubicin treatment on autophagic 
activity. Animals were either treated with DXR (5 mg/kg) or starved for 24 hours or a 
combination of prior starvation following DXR treatment. Apoptotic cell death was measured 
using western blot analysis. Bar graphs show: A) LC3 II and B) p2/SQSTM1 protein levels 
(normalized to β-actin vs control). Values are expressed as means ± SEM (n=3), A:***p < 0.0001 
vs control. B: **p < 0.001 vs control *p < 0.05 vs DXR. Abbreviations- DXR: Doxorubicin; STS: 
Short-term starvation; AU: Arbitrary Units. A representative blot is shown. 
 
 
3.8 The effect of short-term starvation and doxorubicin 
treatment on p-AMPK (oxygen sensor) and p-mTOR 
(energy sensor) in tumour bearing mice 
 
 
Phospho-AMPK-α (p-AMPK) and phospho-mTOR (p-MTOR) as markers of 
oxygen and energy sensing respectively, were assessed by western blotting. 
Phospho-AMPK-α was significantly higher in the DXR treated group when 
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compared to the control (7.052 ± 0.494 fold vs 1.000 ± 0.000 fold, p < 0.0001) 
(Figure 3.8.1 A). Phospho-mTOR activity significantly decreased with DXR 
(0.409 ± 0.013 fold vs 1.000 ± 0.000 fold, p < 0.0001) and significantly 
increased with STS (1.234 ± 0.044 fold vs 1.000 ± 0.000 fold, p < 0.001) when 
compared to the control. The combined treatment of STS+DXR significantly 
increased p-mTOR when compared to DXR (1.140 ± 0.025 fold vs 0.409 ± 
0.013 fold, p < 0.0001) (Figure 3.8.1 B).  
 
 
 
Figure 3.8.1: The effect of short-term starvation and doxorubicin treatment on cellular AMPK 
and mTOR phosphorylation. Animals were either treated with DXR (5 mg/kg) or starved for 24 
hours or a combination of prior starvation following DXR treatment. Apoptotic cell death was 
measured using western blot analysis. Bar graphs show: A) p-AMPK and B) p-mTOR protein 
levels (normalized to β-actin vs control). Values are expressed as means ± SEM (n=3), A: ***p 
< 0.0001 vs control DXR. B: ***p < 0.0001 vs control, **p < 0.001 vs control, ###p < 0.0001 vs 
DXR. Abbreviations- DXR: Doxorubicin; STS: Short-term starvation; AU: Arbitrary Units. A 
representative blot is shown. 
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Chapter 4 - Discussion 
4.1 Introduction 
 
Breast cancer is a major contributor to the mortality of women worldwide. The 
essence of this neoplastic disease lies in the ability of cancer cells to sustain 
chronic cell proliferation which allows for progression to malignancy. Owing to the 
conceptual progress made in the last decade, it has become established that this 
phenomena corresponds to adjustments of energy metabolism in order to fuel cell 
growth and division. This has led to one of the emerging hallmarks of cancer, 
namely the reprogramming of energy metabolism (Hanahan and Weinberg, 2011).  
 
Targeting metabolism is an attractive new paradigm for investigation because of 
the increased metabolic fragility of cancer. The understanding and development of 
clinically available therapies capable of modulating metabolism is thus critical. Most 
studies that have been conducted focused on either omitting or decreasing 
glucose, fatty acids and amino acids from the microenvironment of tumors. 
However, recent clinical and pre-clinical studies investigating complete nutrient 
deprivation for extended periods of time during cancer treatment showed promising 
results (Raffaghello et al., 2008). However, more studies need to be conducted to 
clearly demonstrate the beneficial effects of shorter and more endurable periods of 
starvation. Thus, we aimed: Firstly, to establish a time point at which MCF12A 
breast epithelial cells are protected against starvation; secondly, to determine the 
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effect of short-term starvation on doxorubicin-induced cell death; thirdly, to assess 
the activity of autophagy, AMPK and mTOR in our experimental conditions and 
finally, to assess these aims using an in vivo model. 
 
4.2 In vitro study 
 
4.2.1 The effect of various hours of starvation on cell viability and cell death  
Our results demonstrated that MCF12A cells maintained cell viability following 3 
hours of starvation, however cell viability significantly decreased and cell death 
significantly increased following 6 hours of starvation, persisting till 48 hours 
(Figure 3.1.1B, Figure 3.1.2 B and Figure 3.1.3 B, respectively). In contrast, 
MDAMB231 remain viable until 24 hours of starvation after which a significant 
decrease in cell viability and an increase in cell death occurred at 48 hours (Figure 
3.1.1 A, Figure 3.1.2 A and Figure 3.1.3 A, respectively). These findings clearly 
demonstrate the resilient nature of breast cancer cells to total nutrient deprivation 
in comparison to normal breast epithelial cells. The normal breast epithelial cells 
showed no significant decreases in cell viability or significant increases in cell 
death following 3 hours of starvation. This time point was therefore chosen for 
further in vitro experimental analysis in this study as we aimed to establish a time 
frame at which the non-cancerous breast epithelial cells were not adversely 
affected by the starvation treatment. 
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4.2.2 The effect of short-term starvation on doxorubicin-induced cell death 
In our study, a concentration of 5 µM of doxorubicin induced ±40% cell death in the 
MDAMB231 cells (cancer cells) and ±30% cell death in the normal MCF12A cells. 
In a clinical setting doxorubicin is administered intravenously over a brief period of 
time at a dose of 60 - 75 mg/m2 with plasma concentrations peaking at a range 
between 5 and 15 µM. Since ± 75% of doxorubicin is bound by plasma proteins, 
the peak concentration of free doxorubicin available to induce its apoptotic effects 
is between 1.25 and 3.75 µM (Liu, 2008). Previous work done in our group 
demonstrated a significant decrease in cell viability in the MDAMB231 cells treated 
with 5 µM of doxorubicin for 24 hours (data not shown) (Thomas, PhD thesis, 
2012) (Available: http://scholar.sun.ac.za/mark peter thomas). Since, 5 µM of 
doxorubicin is within the clinically accepted dose range of 0.1 - 5 µM in vitro (Liu, 
2008), this was the reasoning for using this specific concentration in our study. 
 
In our study, results were further validated by western blot analysis of apoptotic 
markers as a significant increase in cleaved caspase-3 in MDAMB231 cells were 
observed when treated with doxorubicin compared with the control group (Figure 
3.2.2 A). Our results are in accordance with another study where doxorubicin-
induced apoptosis induced poly (ADP-ribose) polymerase cleavage (PARP) and 
activation of caspase-3 (Lee et al., 2002). However, despite its wide-spread clinical 
use, doxorubicin, as with most chemotherapeutic drugs, is highly toxic and 
detrimental to healthy viable tissue in the body. Thus, urgent treatment modification 
is required to attenuate doxorubicin toxicity in normal cells. 
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The results obtained from the MTT assay, clearly demonstrated that the combined 
treatment of starvation and doxorubicin protected normal MCF12A breast epithelial 
cells against doxorubicin-induced cytotoxicity. Furthermore, it also sensitized 
MDAMB231 to doxorubicin-induced cell death (Figure 3.2.1 A & Figure 3.2.2 A and 
B). These results confirm the findings of other studies which demonstrated that 
low-serum media protected normal glial cells but not glioma and neuroblastoma 
cancer cell lines against the toxicity of the chemotherapeutic drug, 
cyclophosphamide (Raffaghello et al., 2008).  
 
In addition, it was also reported that patients who starved 48 - 140 hours pre-
chemotherapy and 5 - 56 hours post-chemotherapy experienced reduced toxic 
side-effects (Raffaghello et al., 2010). Some of these side-effects included 
decreased headache, nausea, vomiting, abdominal cramps, hair loss and short-
term memory loss. It is known that cancer cells have a high metabolic demand that 
allows them to sustain high proliferation rates. Thus, this concept of using 
starvation as a method of sensitization aims to further exploit this fact, leaving 
cancer cells more vulnerable to the cytotoxic effects of chemotherapy.  
 
Images obtained during live cell imaging, revealed distinct observable 
morphological changes which occurred as cancer cells progressed through 
apoptosis. The highest degree of cell death occurred in the group subjected to 
starvation and doxorubicin treatment of 24 hours, in which distinct nuclear 
fragmentation and nuclear condensation was clearly observed  (Figure 3.4.2) 
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confirming the results discussed above and further substantiating  that short-term 
starvation sensitizes cancer cells to doxorubicin- induced cell death.  
 
4.2.3 The effect of short-term starvation and doxorubicin treatment on 
autophagic activity 
Our results demonstrated high basal autophagic activity under control conditions 
(Figure 3.3.1 A). The MDAMB231 cells utilised in our study is an aggressive cancer 
cell line which possesses ras-mutations. Our results is thus in agreement with the 
finding that activated Ras promotes tumourigenesis but also up-regulates basal 
autophagy which is essential for maintaining mitochondrial metabolism, cellular 
viability and cell growth both in vitro and in vivo (Guo et al., 2011).  
 
Interestingly, doxorubicin only and starvation only significantly decreased this high 
basal level of autophagy when compared to the control group. Furthermore, the 
combination group of doxorubicin plus starvation further attenuated the autophagic 
response when compared to the doxorubicin group. These results are confirmed 
with a significant increase in accumulation of p62 which was observed in the 
combined group compared with the doxorubicin only group (Figure 3.3.1 B). This 
was also associated with an increase in apoptosis in our results. Our results 
confirmed those by Qadir and co-workers (2008) who have demonstrated that 
siRNA of Beclin-1, ATG5 and ATG7 (genes associated with autophagy) which 
attenuates the autophagic response by causing defects in autophagic degradation, 
resulted in increased apoptosis when cells were exposed to the 
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chemotherapeutical drug, tamoxifen. Tiwari and co-workers (2008) have also 
shown that the silencing of ATG proteins sensitized cancer cells to radio- and 
chemotherapy. 
 
On the other hand, it is well known that autophagy plays a critical role in 
maintaining cellular homeostasis during cellular stresses such as chemotherapy 
and nutrient or growth factor depletion, and thus represents a pro-survival pathway 
(Denis and Codogno, 2003; Pouyssegur et al., 2006). This fact is supported by 
studies which showed that chemotherapy agents such as doxorubicin induced an 
increased autophagic response in cancer cells (Lambert et al., 2008; Manov et al., 
2011). Additionally, studies which deprived cancer cells of amino acids or glucose 
reported elevated levels of autophagy (Liang et al., 1999; DiPaola et al., 2008). A 
more recent study revealed that ras-mutated cancer cells subjected to total nutrient 
deprivation for 3 hours displayed elevated levels of autophagy (Guo et al., 2011). 
These conflicting results may be due to different cell models, different 
chemotherapeutic agents and concentrations utilized as well as duration of 
treatment regimes employed. Additionally, it has been previously demonstrated in 
our group that during amino acid starvation, autophagy displays a bi-phasic 
response (Thomas, PhD thesis, 2012) (Available: http://scholar.sun.ac.za/mark 
peter thomas). This observation indicates that autophagic activity fluctuates 
between time points thus, in order to characterise the role of autophagy in this 
study, it is imperative to assess autophagic activity at various time points. 
Furthermore, this observation possibly suggests that the initial peak in autophagic 
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activity in these cells is used as a survival mechanism during nutrient deprivation, 
whereas the second peak may potentially be detrimental to cancer cells since 
autophagy is often associated with other forms of cell death such as apoptosis 
(Kobayashi et al., 2010). Since, dying cells are observed to contain 
autophagosomes, it is unclear whether autophagy promotes cell death or is up-
regulated in an effort to prevent cell death (Gozuacik and Komchi, 2007).The role 
of autophagy in tumourigenesis therefore remains to be clearly elucidated, as 
some studies indicate that autophagy plays a role in tumour progression and 
others confirm that it contributes to cell death.  
 
4.2.4 The effect of short-term starvation and doxorubicin treatment on p-
AMPK (oxygen sensor) and p-mTOR (energy sensor) 
The results obtained from western blot analysis performed on MDAMB231 cells 
showed a significant increase in p-AMPK in response to 3 hours of starvation as 
expected, as it is well known that this kinase is activated in response to a low 
AMP/ATP ratio due to cellular stresses such as starvation (Figure 3.8.1 A). The 
activation of p-AMPK coincided with a significant decrease of p-mTOR (Figure 
3.8.1 B). Interestingly, this elevated p-AMPK and attenuated p-mTOR levels in the 
starvation group were not associated with increased autophagy or apoptotic cell 
death. As such a response usually corresponds with an up-regulation of 
autophagy, our results contradict this fact as autophagy significantly decreased in 
response to starvation. It might be that if the starvation period was extended, that 
increased autophagy would have been observed in our model. These results 
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confirm the fact that cancer cells possess the innate ability to evade the earliest 
forms of cell death by adapting to declining ATP levels through the activation of 
AMPK (Buzzai et al., 2005) which reduces mTOR activity thus resulting in a 
decrease in protein synthesis. 
 
Various cancers, including human breast cancers possess a mutation in the 
tumour suppressor phosphatase and tensin homologue deleted from chromosome 
10 (PTEN) (Meric-Bernstam and Gonzalez-Angulo, 2009). A subsequent loss of 
PTEN was shown to lead to a constitutive activation of mTOR following doxorubicin 
treatment in prostate cancer cells conferring resistance to doxorubicin-induced cell 
death (Grunwald et al., 2002). However, doxorubicin treatment only in our study 
showed no significant changes in p-mTOR expression. However, starvation with 
doxorubicin treatment induced a significant decrease in p-mTOR which was 
unexpected, since it is generally believed that inhibition of mTOR is associated with 
an increase in autophagy which was not observed in our results. The attenuation of 
mTOR in the combination treatment group in our experimental model might thus be 
associated with an inhibition of protein synthesis which could subsequently reduce 
growth and cellular proliferation of cancer cells (Figure 3.8.1 B). 
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4.3 In vivo study 
 
4.3.1 The effect of short-term starvation on doxorubicin-induced cell death 
          and autophagy, p-AMPK (oxygen sensor) and p-mTOR 
         (energy sensor) in tumour bearing mice. 
Although no significant changes were observed in tumour volumes between the 
various treated groups (Figure 3.5.1) for reasons indicated before, significant 
changes were obtained on a molecular level. In contrast to the results obtained 
from the in vitro experiment, in which short-term starvation sensitized breast cancer 
cells to doxorubicin-induced cell death, the in vivo analysis revealed a significant 
decrease in cell death in the combination group (starvation and doxorubicin 
treatment) in comparison to mice which were treated with doxorubicin only. 
Although the combination treatment did induce a significant increase in apoptosis 
compared to the control group, it was significantly lower when compared to the 
doxorubicin only group. Raffaghello and co-workers (2008), on the other hand, did 
observe a decrease in tumour volume and an increase in apoptosis in a study in 
when mice were starved for 48 hours prior to chemotherapeutic treatment with 
etoposide (Raffaghello et al., 2008). These conflicting results might be due to 
different chemotherapeutic agents and differences in the periods of starvation. 
 
Contrary to the in vitro results, doxorubicin caused a significant increase in p-
AMPK and a decrease in p-mTOR activation with a subsequent increase in 
Stellenbosch University  http://scholar.sun.ac.za
83 
 
autophagy which was confirmed by the elevated LC3 II levels and attenuated p62 
levels in our model. These results are confirmed by others who reported the same 
cellular mechanism via which autophagic activity is upregulated in the treatment 
group (Singh and Cuervo, 2011).  
 
Interestingly, the starvation group and the combination group showed a significant 
increase in p-mTOR. This might be indicative of increased protein synthesis to 
counteract the effect of starvation in this model. This may further indicate that 
mechanisms other than autophagy were up-regulated to provide nutrients. Such 
mechanisms in an in vivo setting may involve interplay of hormones which affect 
molecular responses such as the body’s innate response to up-regulate both 
gluconeogenesis and glycogenolysis to provide substrates for energy during 24 
hours of starvation, hence compensating for this bioenergetics compromise. Thus, 
for future in vivo studies more time points should be considered as a part of 
preliminary experimentation.  
 
Additionally, since tumours are heterogeneous masses composed of metastatic 
cells and stromal cells which are both vital for the proliferation and survival of 
malignancies, protection of tumourigenic or non-tumourigenic cells during 
chemotherapy or starvation could directly confer a survival advantage onto treated 
cancers. Hence, it would be important to identify the various cell types which 
comprise biological tumours before experimental procedures are conducted and 
then to take into consideration how these cell types may affect the response of 
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cancer cells to treatment in an experimental setting. Future studies that employ in-
vivo whole animal imaging techniques as well as cell sorting will contribute to 
address these challenges.    
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Chapter 5 – Final Conclusions 
 
The remarkable success of the few cell culture and animal models as well as from a 
recent clinical trial which exploits the concept of starvation has gained much 
attention and shows great promise. However, if short-term starvation could prove to 
be safer and reproducible, then this form of differential therapy would be much easily 
translated into a clinical setting to improve the quality of life and perhaps even 
reduce or prevent some of the detrimental side-effects of patients receiving 
conventional chemotherapy.  
 
In the in vitro model of our study, we have established that short-term starvation has 
the potential to sensitize breast cancer cells to doxorubicin-induced cell death. 
Additionally, it appears that this therapy combination aids in protecting breast 
epithelial cells against the toxic effects of doxorubicin. However, translation of these 
results in our in vivo study is worth further exploration by examining these effects 
under various time-points in order to achieve this desired effect. Conclusively, short-
term starvation during chemotherapy is a realistic avenue for adjuvant therapy but 
there is a need for further investigation. 
 
No studies to date have investigated autophagy in the context of short-term 
starvation therapy during anticancer treatment regimens. Cancer cells are known to 
innately up-regulate autophagy to meet their metabolic demands. This was 
confirmed in the MDAMB231 cell line utilised in our study which demonstrated high 
basal autophagic activity. Although starvation induced a rapid increase in p-AMPK 
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levels and the subsequent inhibition of p-mTOR, no changes in autophagy was 
observed. These results confirm the fact that cancer cells possess the innate ability 
to evade the earliest forms of cell death by adapting to declining ATP levels through 
the activation of p-AMPK. What was interesting and probably of clinical value, is the 
fact that cell death increased and autophagy decreased when cells were starved and 
treated with DXR. Since, autophagy is associated with chemo-resistance and there 
is an urgent demand for autophagic inhibitors which can be utilized clinically; short-
term starvation with chemotherapy may serve as a safe and novel approach to inhibit 
autophagy for future therapeutic benefits. However, to identify the precise role that 
autophagy is playing in this study, autophagic inhibitors and inducers as well as 
additional time points should be utilized as it has been previously demonstrated in 
our group that autophagy during amino acid starvation demonstrated a bi-phasic 
response (Thomas, PhD thesis, 2012).  
 
As the interest in modification of autophagy for therapeutic benefit ensues and novel 
strategies such as starvation during high-dose chemotherapy are explored, it is 
crucial that future studies undertaken are aimed at developing  methods to determine 
how various cancers respond to autophagy during treatment and if increases in 
autophagy confers a survival advantage. Furthermore, it is imperative to identify the 
underlying mechanisms influencing the beneficial effects of short-term starvation, 
prior to being translated into a clinical setting.  
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Chapter 6 - Limitations and Future 
directions 
 
One of the major challenges faced by biological scientists is the inability to directly 
translate in vitro protocols to an in vivo setting. This is greatly attributed to the fact 
that most in vitro work is done on monolayer cell culture models. This is an imprecise 
representation of biological tumours which are three-dimensional in nature and 
highly heterogeneous containing not only tumourigenic cells but a network of non-
tumourigenic cell types as well. A step towards ameliorating this concern would be to 
introduce the growth of 3-dimensional spheroid cultures in vitro, thereby providing a 
more relevant representation of tumour structure and functional dynamics.  
 
In the context of inducing starvation in an in vivo model, it is imperative to consider 
the innate responses of a physiological system in maintaining homeostasis during 
periods of starvation. Such a response would be to up-regulate gluconeogenesis and 
glycogenolysis to provide substrates for energy production which could affect the 
results of in vivo experimentation. Additionally, since cancer cells form a dynamic 
relationship with the tumour microenvironment, other factors such as hypoxia, 
changes in hormonal levels and genetic alterations may influence the response to 
starvation further. These parameters are controlled in an in vitro setting but are 
challenging to control in an in vivo model thus contributing to the complexity of 
extrapolating molecular relationships. 
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Another significant issue in oncology is tumour heterogeneity. Since tumors are 
masses composed of metastatic cells and stromal cells which are both vital for the 
proliferation and survival of malignant cells, protection of tumourigenic or non-
tumourigenic cells during chemotherapy or starvation could directly confer a survival 
advantage onto treated cancers.  
 
In the context of clinical trials, oncologist would have to extensively examine patients 
before introducing starvation into their chemotherapeutic regimen thus, varying 
among patients depending on the extent of tumour progression and their individual 
health status. This may be limiting, as such a protocol may not be suitable for all 
cancer patients. 
 
Breast cancer represents a multitude of different diseases with intra-tumoural and 
inter-tumoural genetic and epigenetic alterations. In the future, it will be paramount to 
understand how these defects originate during disease progression and to identify 
the key mechanisms underlying chemotherapy resistance before being exploited 
clinically, for therapeutic benefit. As we realize the complexity resulting from the 
plethora of factors which manifests this multifaceted disease, conducting clinical 
trials to assess novel agents in combination with chemotherapy and other modalities 
such as dietary modification is becoming an increasingly important trend.  
 
Since this study focused primarily on mechanisms induced by cancer cells in 
response to short-term starvation, the same experiments should be performed on the 
MCF12A breast epithelial cell line to further complement our study. Additionally, to 
elucidate the exact role played by autophagy in this scenario, autophagic inhibitors 
Stellenbosch University  http://scholar.sun.ac.za
89 
 
and inducers should be utilised as well as additional time points in both in vitro and in 
vivo should be considered as autophagy is known to display a rhythmic response to 
starvation.  
 
Despite the molecular mechanisms of autophagy identified in an in vitro setting, 
there continues to be a lack of physiological relevant in vivo information on the role 
of autophagy in neoplastic disease progression. By employing the use of green 
fluorescent protein-LC3 expressing transgenic mice, we can further investigate and 
characterise the in vivo effects of starvation and chemotherapy on the stimulation 
and control of autophagy in a variety of tissues. 
 
As cancer is being increasingly characterised as a metabolic disease, an interesting 
approach to this study would be to further characterise the metabolic profiles of both 
MCF12A cells and MDAMB231 cells in response to short-term starvation. Thus, 
amino acids, fatty acids, glucose and ATP should be analysed. Since, cancer cells 
have high glycolytic activity; it would be of value to distinguish between the different 
molecular mechanisms involved when a cancer cell is starved as opposed to a non-
starved cancer cell. This would aid in a comprehensive understanding of how cancer 
cells respond to starvation and may also reveal a selection of biomarkers which may 
be manipulated for therapeutical benefit. 
Investigating mitochondrial fate during starvation would be an exciting avenue worth 
exploring. Changes in mitochondrial mass and morphology as well as characterising 
the role of mitochondria during autophagy can be further analysed. Future research 
may also determine if other organelles such as the endoplasmic reticulum and 
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peroxisomes are also affected in their shape or activity during autophagy under a 
nutrient deprived scenario. 
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Appendices 
Appendix A 
Protocol 1: Cell culture 
• Before experimental work in the laminar flow began, hands were thoroughly 
washed and sprayed with 70% ethanol and gloves were worn and sprayed with 
70% ethanol once again to ensure sterility. 
• T75 flasks containing E0771 breast cancer mouse cells, that were approximately 
60-70% confluent were split into 6-well plates of ± 150 000 cells per well of 
containing 2 ml of media or ± 300 000 cells per T25 flask containing 4 ml of media 
for experimental procedures. 
• Cells were washed with warm PBS (see Appendix B) to remove growth medium 
(see Appendix B) completely and dead cells. 
• Cells were trypsinised using trypsin (3 ml) to release the adherent cells. 
• The flask was then placed in an incubator, set at a low shaking speed for 3-mins at 
37ºC. Cells were then viewed under a microscope to ensure detachment; if cells 
were not loosened the flask was gently tapped. 
• Once the cells were loosened, warm growth medium (Double the amount of trypsin 
added = 6ml) was added to the flask to neutralise the trypsin. This was done to 
prevent the trypsin from killing the cells. 
• This solution (growth medium, trypsin and cells) were then transferred to a 15 ml 
falcon tube and centrifuged at 1500 rpm for 3 minutes. 
• The supernatant (trypsin+ growth medium) was removed and the pellet (cells) was 
re-suspended with 3 ml fresh growth medium using a pipette. 
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• To determine the average number of cells , 20 µl of the cell suspension was pipette 
onto a haemocytometer (see protocol 2) 
• The number of cells per millilitre was calculated (see protocol 2) 
 
Protocol 2: Cell counting using a haemocytometer.  
• The haemocytometer was first cleaned by wiping with 70 % ethanol and then a 
moistened with breathe on the surface to allow for the coverslip to attach tightly. 
• The re-suspended cell suspension (20 µl) was then pipette, 10 µl onto side A and 
10 µl onto side B on the haemocytometer, using a micropipette. 
• Through capillary action the cell suspension filled both counting grids (side A and 
B) (see diagram below) 
• The total number of cells was counted by counting areas 1 to 8 in both counting 
grids. The average number of cells was then calculated and multiplied by 10 000 to 
get the number of cells per millilitre of the original cell suspension. 
   
 
 
 
  
 
 
 
 
 
 
1 
2 
3 
4 
5 
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Protocol 3: Cell Harvesting  
• This process removes the cells from the plastic substrate and breaks cell-to-  
cell bonds as gently as possible  
 
• The old medium was discarded either by careful decanting or with a sterile pipette 
and the monolayer of cells was washed quickly with ice cold PBS. This wash step 
was repeated three times to remove all traces of FBS. 
 
 
• The wash medium was decanted and then 250 μl (6-well plates) or 1000 μl  
(25 cm2 flask) of RIPA buffer (see appendix G) was added to each well other 6-
well plate and flasks and placed on ice for 3-5 min  
 
• The plates or flasks were swirled to make sure that the surface area was covered 
with the buffer  
 
• After the time period had lapsed, the cells were scraped from the surface of each 
well and flask using a sterile cell scraper  
 
• The buffer containing the cells was then pipetted into already chilled eppendorf 
tubes and stored at -80 °C until further experiments were carried out.  
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Protocol 4.1: Extraction of proteins from cell samples   
• Work on ice at all times to avoid the denaturing of proteins  
• Thawed cell samples (from protocol 3) were placed in chilled test tubes and  
sonicated. This process ruptures the cell walls in order to release proteins  
• The metal piece of the sonicator was rinsed before and after use with distilled 
water  
• After sonicating the cells, the cell solution was transferred into a chilled eppendorf 
tube and centrifuged at 4 ºC and 8x103 rpm for 10 min.  
 
 
Protocol 4.2: Extraction of proteins from tissue samples  
• Work on ice at all times to avoid the denaturing of proteins  
• Thawed cell samples were first cut into smaller pieces before being placed in 
chilled test tubes containing 1000 µl of RIPA buffer and sonicated. This process 
ruptures the cell walls in order to release proteins  
• The metal piece of the sonicator was rinsed before and after use with distilled 
water  
• After sonicating the contents of the tubes were transferred to eppendorf tubes that 
were placed on ice.  
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Protocol 5: Protein determination with Bradford reagent  
Bradford Reagent: (5x concentrated) 
Dilute 500 mg of Coomasie Brillant Blue G in 250 ml 95 % ethanol 
Ass 500 ml of Phosphoric acid ad mix thoroughly 
Make up to 1 L with dH2O 
Filer and store a 4˚C 
 
Bradford Working Solution 
Dilute stock in 1:5 ratios with dH2O 
Filter using 2filter paper at the same time 
Solution should be light brown color 
 
Bradford quantification 
• Thaw a 1mg/ml BSA stock solution 
• Thaw protein sample if it in -80˚C freezer – Keep on ice at all times 
• Make up working solution of 100 ul BSA: 400 µ dH2O. Vortex mixture 
• Make 7 eppendorf tubes for the standards as well as tubes for samples to be 
tested 
• Now add BSA water to marked Eppendorf tubes as follows 
• Work on ice at all times to avoid the denaturing of proteins  
• For protein determination, make a 1:5 dilution of the Bradford reagent using 
distilled water.  
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• This solution needs to be filtered twice using 2 pieces of filter paper. The Bradford 
reagent is light sensitive therefore remember to use foil or work in the dark room 
when filtering  
• Once the Bradford reagent has been made, a standard curve needs to be made in 
7 different eppendorf tubes as follows:  
Blank 0 µl BSA 100 µl dH2O 
2 µg protein 10 µl BSA 90 µl dH2O 
4 µg protein 20 µl BSA 80 µl dH2O 
8 µg protein 40 µl BSA 60 µl dH2O 
12 µg protein 60 µl BSA 40 µl dH2O 
16 µg protein 80 µl BSA 20 µl dH2O 
20 µg protein 100 µl BSA 0 µl dH2O 
Each sample 0 µl BSA 95 µl dH2O 5 µg of sample protein 
 
• Vortex the solutions thoroughly and let them stand in ice for ±5 min  
• Zero the spectrophotometer using the blank and then read the absorbance values 
at 595 nm using the Simple Reads program  
• Once the absorbance readings were recorded, the readings were transferred onto 
an Excel spreadsheet and a standard curve was created.  
 
 
Samples:  
• Pipette 5 μl from each sample that was centrifuged into a new eppendorf tube and 
then add 95 μl distilled water and 900 μl Bradford reagent. 
• Vortex solution and then read the absorbance values at 595 nm using the Simple 
Reads program  
• Using excel, plot the standard curve with protein concentration on the x-axis and 
the mean OD on the y-axis (see example below). Add in the absorbance  
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Protocol 6: Western Blot  
 
BioRad pre-cast gradient gels were used (4-15%).  
 
Loading samples  
 
• Place yellow well guide on top of apparatus in the middle compartment  
• Using a 20 μl pipette, add 10 μl peqGOLD pre-stained marker in first well on the left 
and then your samples from the second well. Use a clean tip for every sample and 
marker  
• Once all samples have been loaded, remove the well guide and add running buffer 
on the outer compartment up to ½ way from the bottom  
• Place green lid on apparatus and attach electrodes – red to red and black to black  
• Turn on electrophoresis machine and allow samples to run for 10 min at 400 mA 
and 100 V (fixed)  
• Run samples for a second time for 20 min at 400 mA and 200 
 
Transfer of proteins to membrane 
Performed using BioRad transfer packs 
• Go back to gel apparatus and remove the U-shaped core-latch. Remove the glass 
plates and separate them very carefully to avoid tearing the gel. Cut off the wells 
(stacking gel) and place the remaining (separating) gel in transfer buffer  
• Add the gel on top of membrane  
• Finally, place another other piece of blotting paper provided on top. 
• Close the apparatus and then supply power for electron transfer: 100V, 0.5A 
30 minutes  
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• Once the time has elapsed, open semi-dry apparatus and remove the blotting 
papers on top carefully.  
• Place membrane in blocking solution for a minimum period of 1hr on the belly 
dancer on lowest setting or leave in the fridge (4 ºC) overnight  
Specific binding of proteins  
• Wash membrane 3X (5 min each) with TBS-tween  
• Make primary antibody solution in a 50 ml falcon tube. Roll the membrane 
containing transferred proteins facing the inside and the marker facing the bottom 
and place inside the falcon tube  
• Mix on the rotating machine in the corridor fridge for a minimum period of 8 hr or 
leave overnight  
• Wash membrane 3X (5 min each) with TBS-tween 
• Make secondary antibody solution in a 50 ml falcon tube and add to membrane. 
Mix on the belly dancer or tube roller on lowest setting for 1 hr 
 
 
 
 
Exposure  
• Wash membrane 3X (5 min each)  
• Mix ECL cocktails (500 μl solution A + 500 μl solution B) in falcon tube  Drain 
excess liquid from membrane using tissue paper and add the ECL on the 
membrane and leave on for 1min  
• Place in Chemi-Doc system tray and roll out bubbles before preparing software for 
image viewing. 
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Stripping membranes  
• Wash membrane 2X (5 min each) in dH2O at room temperature  
• Wash membrane 1X (5 min) in 0.2 M NaOH at room temperature  
• Wash membrane 2X (5 min each) in dH2O at room temperature  
• Place membrane in blocking solution and carry on as usual for western blotting (This 
procedure completely removes all antibodies)  
 
Protocol 7: Trypan Blue Cell Exclusion Technique 
Three independent experiments were conducted in triplicate. 
Method: 
• After 24 hour of treatment, 6-well plates containing treated cells were removed 
from the hypoxic and normoxic incubators. 
• Medium was removed from cells in each well, washed with warm PBS and 
trypsinized (Protocol 1). 
• Cell solution containing Trypsin was neutralised with warm growth medium, 
followed by centrifugation at 1300-1500 rpm for 3 minutes. 
• The cells were analysed separately from each well and were re-suspended in 500 
µl of warm PBS. 
• From this suspension, 10 µl was removed into a 1ml eppendorf and 10 µl of Trypan 
Blue Dye (Invitrogen) was added to this. 
• The cells suspension with the added dye was then pipetted onto counting slides 
(Invitrogen) 
Using the Invitrogen Automatic cell counter, the total numbers of viable cells were 
calculated automatically and data recorded. 
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Protocol 8: MTT Cell Viability Assay 
Method: 
• Three independent experiments were conducted in triplicate. 
• An Isopropanol solution (1%): containing 1 ml concentrated HCl and 99 ml 
Isopropanol was made.  
• Triton solution (0.1 %) containing 0.1 ml Triton-X-100 was made up to 100 ml with 
distilled water.  
• An Isopropanol / Triton solution was made in a 50:1 ratio, where 50 ml of 1% 
Isopropanol was added to 1 ml of 0.1% Triton. 1%  
• MTT (0.01 g/1 ml PBS) solution was made up just before use. MTT is 
photosensitive, thus the solution was covered in foil. 
• Medium was removed from treated cells. 
• PBS (1.5 ml) and MTT (500 μl) was added and allowed to incubate, in 6 well plates 
covered with foil for 1 for 1 hour at 37ºC. 
• After a hour if no cells had loosened. 2ml of the Isopropanol / Triton solution was 
added to each well and plates covered in foil were placed on a shaker for 5 
minutes. 
• The contents of each wells was transferred to 2 ml eppendorf tubes, centrifuged for 
2mins at RPM 1500. 
• The absorbance values of the supernatant were read at 540 nm using a 
spectrophotometer with Isopropanol / Triton solution was used as a blank. 
• If absorbance was greater than one the supernatant was diluted with the 
Isopropanol / Triton solution and read at 540 nm again. 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
- 11 - 
 
Protocol 9: Caspase-Glo 3/7 Assay  
For this technique, cells were grown and treated on 96-well flat-bottom (enzymatic assay) 
plates and caspase activity was measured as follows:  
• The Caspase-Glo 3/7 reagent was prepared (mix) following the manufacturer’s 
instructions, and was allowed to equilibrate to room temperature  
• The 96-well plates containing cells were removed from the incubator and allowed 
to equilibrate to room temperature  
• 100 μl of the Caspase-Glo 3/7 reagent was added to each well (100 μl) of the plate. 
The plate was then covered  
• The contents of the wells were mixed using a plate shaker at 300-500 rpm for 30 
sec. Incubation followed for 30 min at room temperature  
• The luminescence of each sample in the plate was measured using a plate- 
reading luminometer  
• In addition, blank (containing only medium) wells were treated with the Caspase-
Glo 3/7 reagent. The values from these wells were subtracted from the wells 
containing cells to remove any background noise. 
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Protocol 10: GFP-LC3 Transfection and Live Cell Imaging 
• Cells were cultured in chamber dishes containing 8 wells. 
• 800ng of DNA concentration per sample (well of the 8-chamber dish) 
• Lipofectamin is used as chemical transfection reagent. It is a transient transfection, 
meaning that: 
 1. Not all cells will take up the construct and express protein and  
2. The cells will not express the protein for long (usually the plasmid is released 
during cell cycle or after a few cell divisions).  
• 800ng DNA +50 ul serum free media per sample in one eppendorf tube (A), 
vortex for 3 sec For 4 wells, use 200 ul media + 2.4 ul DNA for the LC3 
• 12 ul lipofectamin + 200 ul serum free media per sample in one eppendorf tube 
(B), vortex for 3 sec 
 
• Incubate both at room temperature for 5 min 
1.  Combine both A and B, vortex, incubate for 20 min at room temp. 
2. Add the DNA/reagent mixture drop-wise onto the dish (containing normal 
growth medium) (100 ul per well) 
 
• Image 24 hrs later (or, change media next day, image 48hrs post transfection) 
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Protocol 11: In vivo Model- Cancer cell inoculation. 
Adapted from Ewens et al. 2006 (doxorubicin plus Interleukin-2 Chemo-immunotherapy 
against Breast Cancer in Mice). 
• Culture E0771 cells until 80% confluent. 
• Digest cultured E0771 cells using tyrosin (0.05% trysin-EDTA from 5 minutes at 37˚C). 
• Centrifuge at 1500 rpm for 3 minutes. 
• Wash cells once with sterile PBS. 
• Count cells and dilute with HBSS to a concentration of 1250 cells/µl (2.5 x 105 cells in 
200µl) 
• Inject the cell suspension in lower abdomen of each mouse, in or near the no. 4 
mammary fat pad (Day 0). 
Mice Subcutaneous injection (SC) 
Adapted from Guideline for Handing, Restrain, Injections and Blood Collection from 
Small Laboratory animals (http://campusvet.wsu.edu/infofac/handing.htm). 
SC injections can be administered easily to mice. The needle in inserted between the folds 
of the skin into the base of the triangle that is form when traction is applied to the skin 
overlying the animal’s scruff. The syringe’s plunger should be retraced to verify that a 
vacuum is created and no blood or tissue fluid can be aspirated.  Subsequently, the plunge 
is depressed releasing the material. In general no greater than 1 ml should be injected per 
SC injection site in adult mice (> 25 grams). Several sites over the animal’s back should be 
used if large volumes must be administrated. In general, needles should be 0.5-10 long 
and 23 ga or larger gauge. 
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Appendix B 
 
Growth Medium 
 
• 500 ml Dulbecco’s Modified Eagles Medium (DMEM) 
• 56 ml Fe ta l Bovine  S e rum (FBS ) 
• 5.6 ml P e ns tre p 
 
 
Hanks Balanced Salt Solution (Used to induce Starvation) 
 
• Contains Magnesium, Calcium and Sodium Bicarbonate, pH 7.0 – 7.4. 
 
 
Phosphate buffer saline 
 
Weigh the following reagents:  
• 16 g Na Cl 
• 0.4 g KCl 
• 2.88 g Na2HPO4 (di Sodium hydrogen phosphate) 
• 0.48 g KH2PO4 (potassium di-hydrogen phosphate) 
 
Adjust pH to 7.4, fill up to the 2 L mark with distilled water and sterilize by 
autoclaving. 
 
 
Running buffer (1 L)  
 
• Weight out 3.03 g Tris, 1.44 g Glycine and 1 g SDS into a 1 L beaker.  
• Add 500 ml distilled water and stir until dissolved  
• Fill up to 1 L with distilled water  
 
 
10X TBS (5 L)  
 
• Weight out 121 g Tris and 80 g NaCl into a 5 L beaker. Add 2.5 L distilled  
• water and stir until dissolved.  
• Adjust pH to 7.6 using HCl and then fill up to 5 L with distilled water  
• For use in Western blotting, take a 1 L measuring cylinder and add 100 
ml  
• 10X TBS and dilute with 900 ml distilled water  
• To make TBST, add 1 ml tween to 1 L diluted solution of TBS  
 
Transfer Buffer  
 
• In a 1 L cylinder, add 100 ml Biorad 10X TG buffer, 200 ml 100% 
methanol and 700 ml distilled water  
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Milk blocking solution (100 ml)  
 
• Weight out 5 g non-fat dry instant milk powder into a beaker. Add 100 ml 
TBS and mix well  
• Finally add 10 μl Tween and mix well. This is sufficient for only one gel 
 
 
RIPA Buffer 
 
• Tris-HCL 2.5 mM 
• EDTA 1 mM 
• NaF 50 mM 
• NaPPi 50 mM 
• Dithiotheitoal 1 mM 
• Phenylmethylsulfony floride (PMSF) 0.1 mM 
• Benzamidine 1 mM 
• 4 mg/ml SBTI 
• 10 mg/ml leupeptin 
• 1% NP40 
• 0.1% SDS 
• 0.5% deoycholate 
 
 Add 1000 μl Triton X-1000 to the solution and finally fill up to 100 ml with 
distilled water and mix thoroughly  
 Aliquot 1000 μl of RIPA buffer into eppendorf tubes and store at -20 ºC  
 
 
BSA (Bovine serum albumin 1 mg/ml)  
 
• For 1 ml BSA, weight out 1mg BSA and add 1000 μl distilled water.  
• For use during Western blotting, this BSA needs to be diluted.  
• Pipette 100 μl from 1 mg/ml BSA in new eppendorf tube and add 400 μl 
distilled water. 
• Mix well. 
 
Bradford Reagent (1 L)  
 
• Weight out 500 mg Coomassie Brilliant Blue G and add it to 250 ml 95% 
ethanol  
• Add 500 ml phosphoric acid and mix well  
• Fill up to 1 L with distilled water and store at 4 ºC  
• For use during Western blotting, this solution needs to be filtered twice 
and then a 1:5 dilution needs to be made  
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3X Sample buffer 
 
• Measure 33.3 ml stacking Tris (0.5 M) and place in a beaker  
• Weigh out 8.8 g SDS and 20 g glycerol and place in the beaker  
• Add a pinch of Bromo-phenol blue to the mixture  
• Add and make up to 75.47 ml with distilled water  
 
 
Tris pH 8.8 (500 ml)  
 
• Weigh out 68.1 g Tris (1.124 M) and 1.5 g SDS (0.3%) and place in a 
beaker. 
• Add 400 ml distilled water, stir and then adjust pH using HCl  
• Add 100 ml distilled water to make the final volume to 500 ml  
 
 
Tris pH 6.8 (500 ml)  
 
• Weigh out 30.3 g Tris (0.5M) and 2g SDS (0.4%) and place in a beaker.  
• Add 400 ml distilled water, stir and then adjust pH using HCl  
• Add 100 ml distilled water to make the final volume to 500 ml  
 
 
Tris pH 6.8 (100ml) for Sample buffer  
 
• Weigh out 6.06 g Tris (0.5 M) and 4 ml 10%SDS and place in a beaker  
• Add 80 ml distilled water, stir and then adjust pH using HCl  
• Add 20 ml distilled water to make the final volume to 100 ml 
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